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Transplanted embryonic stem (ES) cells following myocardial infarction (MI) 
contribute to limited cardiac repair and regeneration with improved function.  Therefore 
novel strategies are still needed to enhance the efficacy by which ES cells differentiate 
into cardiac cell types and inhibit adverse remodeling in the infarcted myocardium.  Our 
studies evaluate whether genetic manipulation of transplanted ES cells employing miR-
1, a pro-cardiac microRNA, and TIMP-1, an anti-apoptotic and anti-fibrotic protein, will 
enhance cardiac myocyte differentiation, inhibit native cardiac apoptosis, and reduce 
fibrosis in the infarcted myocardium.  Furthermore, we assess levels of associated pro-
(caspase-3, PTEN) and anti-(Akt) apoptotic proteins as well as a pro-fibrotic protein 
(MMP-9) in the post-MI and cell transplanted heart.   
microRNAs (miRs) have emerged as critical regulators of various physiological 
processes including development, differentiation, metabolism, and death.  Indeed, miR-
1 plays an integral role in early cardiac development in Drosophila and mice as well as 
mediates differentiation of cardiac myocytes in vitro.  To that end, we generated ES 
cells overexpressing miR-1 (miR-1-ES cells), transplanted them into the infarcted 
myocardium, and evaluated their impact on cardiac myocyte differentiation, myocardial 
repair, and left ventricular dysfunction post-MI. We provide evidence demonstrating 
enhanced cardiac myocyte commitment of transplanted miR-1-ES cells in the mouse 
infarcted heart as compared to ES cell and culture media transplanted hearts.  
Assessment of apoptosis revealed overexpression of miR-1 in transplanted ES cells 
protected host myocardium from MI-induced apoptosis through activation of p-Akt and 
inhibition of caspase-3, PTEN, and superoxide anion production.  A significant reduction 
iv 
in interstitial and vascular fibrosis was quantified in miR-1-ES and ES cell transplanted 
groups compared with control MI.  However, no statistical significance between miR-1-
ES cell and ES cell groups was observed.  Finally mice receiving miR-1-ES cell 
transplantation post-MI had significantly improved heart function compared with 
respective controls.  Our data suggests miR-1 drives cardiac myocyte differentiation 
from transplanted ES cells and inhibits apoptosis post-MI ultimately giving rise to 
enhanced cardiac repair, regeneration, and function. 
Next, we assessed the role of miR-1-ES cells in a chronic model of MI as 
research has shown that apoptosis occurs not only hours but months following 
ischemia.  4 weeks following transplantation into the infarcted myocardium, we provide 
evidence demonstrating reduced cardiac apoptosis in miR-1-ES cell transplanted hearts 
compared to respective controls.  Moreover, we show significant elevation of p-Akt 
levels and diminished PTEN levels in hearts transplanted with miR-1-ES cells as 
determined by enzyme-linked immunoassays.  Finally, using echocardiography, we 
reveal mice receiving miR-1-ES cell transplantation post-MI had significantly improved 
cardiac function compared with animals transplanted with ES cell and culture media.  
Our data suggests that miR-1, when overexpressed in transplanted ES cells, has the 
capacity to inhibit apoptosis long term while attenuating contractility loss. 
In addition to enhancing cardiac-specific donor cell differentiation, improving the 
efficacy by which stem cells promote cell survival and repair in the host myocardium is 
imperative in the pursuit of refining and optimizing stem cell therapy.   To that end, we 
overexpressed TIMP-1, an endogenous inhibitor of apoptosis and fibrosis, in ES cells 
(TIMP-1-ES cells), transplanted them into infarcted myocardium, and evaluated their 
v 
impact on adverse cardiac remodeling.  Immunofluorescence, TUNEL staining, 
caspase-3 activity, ELISAs, histology, and echocardiography were used to assess 
apoptosis, fibrosis, and heart function.  Hearts transplanted with TIMP-1-ES cells 
demonstrated a reduction in apoptosis as well as an increase in p-Akt activity compared 
with ES cells or culture media controls.  Interstitial and vascular fibrosis was significantly 
decreased in the TIMP-1-ES cell group compared to controls.  Furthermore, MMP-9, a 
key pro-fibrotic protein, was significantly reduced following TIMP-1-ES cell 
transplantation.  Echocardiography data showed fractional shortening and ejection 
fraction were significantly improved in the TIMP-1-ES cell group compared with 
respective controls.  Our data suggest that transplanted ES cells overexpressing TIMP-
1 attenuate adverse myocardial remodeling and improve cardiac function compared 
with ES cells. 
Overall, our data suggest that genetic manipulation of ES cells following 
transplantation in the infarcted heart enhances cardiac myocyte differentiation, inhibits 
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CHAPTER ONE: INTRODUCTION  
Prevalence of MI 
By the year 2030, the American Heart Association predicts 40.5% of the United 
States population will have 1 or more forms of cardiovascular disease (CVD)(19).  
Current estimations reveal CVD affects >81 million Americans with more than 10% 
afflicted by MI(19).  MI events are becoming more prevalent, in part, due to the aging 
population, sedentary behavior, and unhealthy lifestyle habits (smoking, diet, etc).  
Recent advancements have been made in pharmaceutical interventions for the 
treatment of MI but long- and short-term morbidity and mortality remain significantly 
elevated(19).  Additionally, heart transplantation has yet to become a feasible option 
due to the scarcity of organ donors.  To that end, novel therapeutic strategies are 
needed to offer alternatives to the current treatments for MI. 
Myocardial Infarction Pathophysiology  
MI involves various intrinsic physiological and pathological changes to the 
myocardium.  Due to prolonged ischemia following an MI event, cardiac myocyte cell 
death occurs(1).  Cardiac cell death within the infarct and peri-infarct regions occurs as 
a result of apoptosis as well as necrosis(3; 15).  Apoptosis, discrete from necrosis by 
varying morphological and biochemical changes, is a highly orchestrated programmed 
cell death characterized by cell blebbing and shrinkage, chromatin condensation, and 
DNA fragmentation.  Apoptosis consequent to MI is commenced through various 
stressors including cytokines, oxidative stress, and DNA damage(1; 14; 15).  Taking into 
consideration the inadequate regenerative capacity of the heart and the limited number 
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of resident cardiac progenitor stem cells, intrinsic mechanisms to replace lost cardiac 
myocytes following MI is ineffectual(24; 30).  In response to cardiac myocyte cell loss 
within the infarcted myocardium, an increase in matrix metalloproteinases (MMPs) 
occurs leading to extracellular matrix (ECM) degradation, increased matrix protein 
production, fibrosis, stiffening of the heart, and cardiac dysfunction. 
Stem Cells in the Infarcted Myocardium 
Within the last decade, investigators have been exploring the potential use of 
cell-based therapies to attenuate cardiac cell damage and death and left ventricular 
dysfunction consequent to MI.  A number of candidate cell types have been 
transplanted in the infarcted myocardium including skeletal myoblasts, bone marrow 
stem cells, bone marrow-derived hematopoietic stem cells, endogenous cardiac stem 
cells, mesenchymal stem cells, induced pluripotent stem (iPS) cells, and ES cells(13; 
21-23; 26).  Although the therapeutic efficacy of the various cell types used for 
transplantation studies have been inconsistent, ES cells possess many desirable traits 
including not only their plasticity but also their ability to influence injured myocardium 
through paracrine mechanisms making them a promising candidate cell type for use in 
post-MI cell transplantation(29).    
ES cells, derived from the inner cell mass of the blastocyst, are pluripotent, 
undifferentiated cells.  They are capable of self-renewal and are able to differentiate into 
cell types arising from all 3 germ layers.  Noticeably, previous studies have 
demonstrated transplanted ES cells into the infarcted myocardium differentiate into all 
cardiac cell types including cardiac myocytes, endothelial cells, and vascular smooth 
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muscle cells(4; 26).  Transplanted ES cells post-MI have further been shown to 
specifically migrate to the area of left ventricular injury, demonstrate engraftment, repair 
and regenerate the injured myocardium, and improve contractile function(27).  In spite 
of previous assimilated knowledge, the efficacy by which ES cells differentiate into 
cardiac myocytes and inhibit adverse remodeling is limited(4; 6; 22; 27).  To that end, 
current research is aimed towards genetic manipulation of ES cells to optimize the 
therapeutic potential of these cells for cell transplantation in the infarcted myocardium. 
microRNA-1 in Cardiac Myocyte Differentiation 
Cardiac myocyte commitment from transplanted stem cells in the infarcted 
myocardium remains a major challenge to post-MI cell therapy.  Previous reports have 
concluded only ~ 5-15% of transplanted stem cells survive and demonstrate 
engraftment compared to the remaining 85-95% of transplanted cells which undergo cell 
death due to apoptosis or necrosis(6; 25; 37).  Of those 5-15% cells which engrafted, 
limited cardiac myocyte differentiation was observed within this cell population (6; 22). A 
multitude of attempts have been made to enhance and drive cardiac myocyte 
differentiation from stem cells using various factors including bone morphogenetic 
protein-2 (BMP2), transforming growth factor β-2 (TGFβ−2) , vascular endothelial 
growth factor (VEGF), insulin-like growth factor-1 (IGF-1) and -2 (IGF-2), activin-A, 
fibroblast growth factor-2 (FGF-2) and -4 (FGF-4), interleukin-6 (IL-6), and epidermal 
growth factor (EGF)(2; 31; 35; 36).  Despite these efforts, the observed donor cell 
differentiation into cardiac myocytes remains insufficient to regenerate adequate de 
novo myocardium to restore the injured heart to pre-MI homeostasis(6; 22) 
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microRNAs (miRs) are small, single-stranded, non-coding RNAs which recognize 
the 3’ untranslated region (UTR) of their target mRNA and modulate gene expression 
through mRNA degradation, translational repression, and deadenylation.  Recently, 
miRs have been identified in the regulation of diverse physiological and pathological 
cellular processes including development, differentiation, proliferation, metabolism, and 
death(7; 12; 16; 20).   Increasing evidence illustrating the ability of miRs to govern 
complex biological processes underscores the potential of genetic manipulation 
imploring miRs for therapeutic applications. 
miR-1, a widely conserved muscle- and cardiac-specific microRNA, has been 
identified as a major regulator of cardiac muscle commitment and differentiation(16; 38; 
39).  Evidence has shown that overexpression of miR-1 in fibroblasts altered the cell 
gene expression towards that of a muscle cell and when overexpressed in C2C12 
myoblasts, miR-1 induced myogenic differentiation as well as associated cardiac 
markers including myosin heavy chain (MHC), myogenin, MyoD, Mef2, and α-actin(5; 
18).  Furthermore, in vitro studies exploiting mouse and human ES cells and cardiac-
derived progenitor cells revealed increased miR-1 expression upon cardiac 
differentiation induction(11; 32; 33).  However, whether miR-1 overexpression in 
transplanted ES cells will drive cardiac myocyte differentiation in the injured 
myocardium is unknown.  
TIMP-1 in Cardiac Remodeling 
In addition to enhancing cardiac-specific donor cell differentiation, improving the 
efficacy by which stem cells promote host myocardium cell survival and repair is 
5 
imperative in the pursuit of refining and optimizing stem cell therapy.  Following MI and 
myocardial cell loss, cardiac remodeling commences in response to increased MMP 
expression.  MMPs are a family of endopeptidases which play a pivotal role in the 
degradation and aberrant production of ECM proteins leading to adverse alterations in 
ventricular architect post-MI.  Tissue inhibitors of metalloproteinases (TIMPs) are 
endogenous protease inhibitors of MMPs.  TIMPs non-covalently bind the active site of 
inert MMP pro-forms, blocking substrate access and activation of MMPs.  TIMP-1 not 
only exhibits anti-fibrotic characteristics, but recently has been shown to be anti-
apoptotic in non-cardiac cell lines(8-10; 17; 28; 34).  Noticeably, we recently reported 
TIMP-1 to be a cytoprotective released factor from ES cells preventing H2O2 induced 
apoptosis in H9c2 cardiomyoblasts(28).  However, the effects of transplanted ES cells 
overexpressing TIMP-1 on host myocardium remodeling post-MI remains obscure. 
Rationale and Aims 
MI is a leading cause of death in the western hemisphere consequent to 
myocardial injury (cardiac myocyte cell death and fibrotic scar formation) sustained 
during prolonged ischemia(3; 19; 25).  The intrinsic regenerative mechanisms of the 
heart are unable to replenish the infarcted myocardium with significant amounts of 
functional cardiac myocytes to compensate for the millions of cells lost during an MI 
event(1; 14).  Additionally, conventional medical options have not been wholly 
successful in catapulting the heart back to pre-MI status.  Recently, exhaustive effort 
has been put into the development of cell transplantation therapy for treatment of MI as 
an alternative method to repopulate the infarcted area with functional cardiac myocytes 
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thus regenerating the apoptotic myocardium and rescuing contractile function.  Previous 
studies have shown transplanted ES cells in the infarcted myocardium engraft, 
differentiate into cardiac cells, and inhibit adverse left ventricular remodeling (apoptosis, 
fibrosis, and hypertrophy)(26; 27).  However, the efficacy by which transplanted ES cells 
differentiate into cardiac myocytes and inhibit adverse remodeling is limited.  Therefore 
current research in stem cell transplantation is now focused on optimization and 
refinement of ES cell populations using genetic manipulation.   
Within the presented research, we generated ES cells overexpressing miR-1, a 
pro-cardiac microRNA, transplanted them into the infarcted myocardium, and evaluated 
their effects on cardiac myocyte commitment, adverse remodeling, and left ventricular 
function in the acute setting of MI.  The goal of the first study was to enhance cardiac 
myocyte differentiation from transplanted ES cells post-MI.  We hypothesized that miR-
1-ES cells would more readily differentiate into cardiac myocytes compared with 
untransfected ES cells following transplantation into the infarcted myocardium.  To test 
our hypothesis, the following aims were proposed: 
1. Determine the effects of miR-1 overexpression in ES cells on cardiac myocyte 
differentiation following transplantation in the infarcted myocardium 
2. Assess the impact of miR-1-ES cells on host myocardium apoptosis following MI 
3. Identify mechanisms of apoptosis inhibition following ES cell transplantation 
4. Resolve the impact of transplanted miR-1-ES cells on left ventricular function 
following MI 
Within the second study, we evaluated the impact of miR-1 overexpression in 
transplanted ES cells on apoptosis and function in the chronic model of MI.  The goal of 
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this study was to demonstrate long term beneficial effects of miR-1 overexpression in 
transplanted ES cells.  We hypothesized that miR-1-ES cells would significantly inhibit 
apoptosis and improve cardiac function 4 weeks following transplantation into the 
infarcted myocardium compared to unmodified ES cells.  To test our hypothesis, the 
following aims were proposed: 
1. Evaluate the impact of transplanted miR-1-ES cells on host myocardium 
apoptosis 4 weeks following transplantation 
2. Elucidate mechanisms of miR-1-ES cell-mediated apoptotic inhibition 
3. Determine the impact of transplanted ES cells overexpressing miR-1 on cardiac 
function 4 weeks post-MI 
Finally, within a third study, we generated ES cells overexpressing TIMP-1, an 
anti-apoptotic and anti-fibrotic protein, transplanted them into the infarcted myocardium, 
and evaluated their impact on apoptosis, fibrosis, and associated cardiac function in an 
acute setting of MI.  The goal of the second study was to optimize the efficacy by which 
ES cells inhibit apoptosis and fibrosis and ultimately left ventricular dysfunction.   We 
hypothesized TIMP-1-ES cells following transplantation into the infarcted myocardium 
would attenuate apoptosis and fibrosis along with improve cardiac function.  To test our 
hypothesis, we proposed the following aims: 
1. Assess the efficacy by which transplanted TIMP-1-ES cells inhibit host 
myocardium apoptosis 
2. Identify mechanisms by which TIMP-1-ES cells mediate apoptotic inhibition 
3. Determine the impact of transplanted TIMP-1-ES cells on cardiac fibrosis 
following MI 
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4. Evaluate the effect of TIMP-1-ES cells on cardiac dysfunction post-MI 
The long term goal of our research is to generate an ideal stem cell population 
for cardiac repair and regeneration following MI which readily differentiates into cardiac 
myocytes, effectively inhibits apoptosis and fibrosis, and significantly restores cardiac 
function.  Generation of such a stem cell population would provide a strong foundation 
to pursue future research transcending these optimized ES cells from the bench to the 
clinical arena.   
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CHAPTER TWO: microRNA-1 TRANSFECTED EMBRYONIC STEM CELLS 
ENHANCE CARDIAC MYOCYTE DIFFERENTATION AND INHIBIT APOPTOSIS BY 
MODULATING PTEN/AKT PATHYWAY IN THE INFARCTED HEART 
Abstract 
microRNAs (miRs) have emerged as critical modulators of various physiological 
processes including stem cell differentiation. Indeed, miR-1 has been reported to play 
an integral role in the regulation of cardiac muscle progenitor cell differentiation.  
However, whether overexpression of miR-1 in embryonic stem (ES) cells (miR-1-ES 
cells) will enhance cardiac myocyte differentiation following transplantation into the 
infarcted myocardium is unknown.  In the present study, myocardial infarction (MI) was 
produced in C57BL/6 mice by left anterior descending artery (LAD) ligation.  miR-1-ES 
cells, ES cells, or culture medium (CC, control) was transplanted into the border zone of 
the infarcted heart and 2 weeks post-MI, cardiac myocyte differentiation, adverse 
ventricular remodeling, and cardiac function were assessed.  We provide evidence 
demonstrating enhanced cardiac myocyte commitment of transplanted miR-1-ES cells 
in the mouse infarcted heart as compared to ES cells.  Assessment of apoptosis 
revealed overexpression of miR-1 in transplanted ES cells protected host myocardium 
from MI-induced apoptosis through activation of p-AKT and inhibition of caspase-3, 
PTEN, and superoxide production.  A significant reduction in interstitial and vascular 
fibrosis was quantified in miR-1-ES cell and ES cell transplanted groups compared with 
control MI.  However, no statistical significance between mir-1-ES cell and ES cell 
groups was observed.  Finally, mice receiving miR-1-ES cell transplantation post-MI had 
significantly improved heart function compared with respective controls (p<0.05). Our 
data suggest miR-1 drives cardiac myocyte differentiation from transplanted ES cells 
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and inhibits apoptosis post-MI ultimately giving rise to enhanced cardiac repair, 
regeneration, and function.   
Introduction 
Following myocardial infarction (MI), various intrinsic pathological processes 
occur within the myocardium including oxidative stress-induced apoptosis giving rise to 
stiffening of heart muscle, impaired cardiac function, and, ultimately, heart failure and 
death(3; 17; 18; 22; 29).  To date, treatment for MI with pharmaceutical agents have yet 
to be wholly successful and due to the scarcity of organ donors, heart transplantation 
has yet to be a feasible option.  Given this, stem cell therapy has gained considerable 
attention as an alternate method to repair or regenerate injured myocardium 
consequent to MI.   Various investigations have demonstrated the ability of stem cells 
transplanted into the infarcted heart to engraft, differentiate into cardiac cell types, 
inhibit apoptosis and fibrosis, and improve cardiac function(4; 16; 28; 29).  However, 
previous reports have revealed transplanted stem cells into the infarcted myocardium 
demonstrate limited cardiac myocyte differentiation(8; 23).   Therefore, innovative 
stratagem aimed at enhancing cardiac myocyte differentiation from transplanted stem 
cells is monumental in the pursuit of optimizing stem cell transplantation for post-MI 
therapy. 
Recently, microRNAs (miRs) have been identified as regulators of various 
physiological and pathological heart processes including  cardiac development, 
differentiation, arrhythmias, hypertrophy, remodeling, and angiogenesis(5; 6; 9; 10; 24; 
36; 44). miRs are small, single stranded, non-coding RNAs usually about 20-24 
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nucleotides in length.  They recognize the 3’ untranslated region (UTR) of their target 
mRNA and negatively regulate gene expression through translational repression, mRNA 
degradation, and deadenylation. Genetic manipulation imploring miRs for therapeutic 
applications has recently gained significant interest in the research community but 
remains in its infancy. 
miR-1, a widely conserved, cardiac- and muscle-specific miR, has been identified 
in early heart development (19; 46; 47).  Previous studies have illustrated a relationship 
between miR-1 expression and myocardial differentiation through regulation of various 
cardiac markers including myosin heavy chain (MHC), myogenin, Hand2, MyoD, Mef2, 
Nkx2.5, Cdk9, and α-actin(7; 36; 47).  However, exploitation of miR-1 in ES cells for 
post-MI therapy has yet to be attempted.  Based on our previous findings and others, 
we hypothesize that overexpression of miR-1 in transplanted ES cells following MI will 
enhance cardiac myocyte differentiation from donor ES cells as well as attenuate MI-
associated myocardial remodeling.  In the present study, our data demonstrates that 
hearts transplanted with miR-1-ES cells contain significantly more donor cell-derived 
cardiac myocytes compared to respective controls.  Additionally, we reveal that 
transplanted miR-1-ES cells significantly inhibit apoptosis through modulation of p-Akt 
and PTEN gene expression.  Moreover, we show miR-1-ES cells attenuate oxidative 
stress in the injured myocardium.  Finally, our data demonstrate enhanced cardiac 
function following transplantation of miR-1-ES cells post-MI.  Our study establishes a 
strong foundation and rationale to pursue future research using microRNAs in the 
ongoing development of ES cell transplantation therapy for the treatment of myocardial 
infarction. 
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Materials and Methods 
ES Cell Culture 
Mouse CGR8 ES cells were passaged and maintained as previously reported 
(33).  In brief, cells were plated on 0.1% gelatin-coated tissue culture dishes in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 15% ES-qualified FBS, 
leukemia inhibitory factor (LIF), glutamine, non-essential amino acids, 
penicillin/streptomycin, β-mercaptoethanol, and sodium pyruvate. 
miR-1-ES Cell Generation  
Mouse pre-miR-1 oligonucleotides (5’-tgc tgT GGA ATG TAA AGA AGT ATG 
Tag ttt tgg cca ctg act gac TAC ATA CTT TTA CAT TCC A-3’ and 5’-cct gTG GAA TGT 
AAA AGT ATG Tag tca gtc agt ggc caa aac TAC ATA CTT CTT TAC ATT CCA c-3’) 
were cloned into a pcDNA 6.2-GW/EmGFP expression vector (Invitrogen) containing 
the selectable marker blasticidin.  The expression of miR-1 and GFP was driven by a 
cytomegalovirus (CMV) promoter.  CGR8 mouse ES cells were transfected with the pre-
miR-1 expressing vectors using Lipofectamine 2000 (Invitrogen).  Selection media 
containing 2 µg/ml blasticidin (Invitrogen) was added 48 hrs post-transfection and was 
changed every 48 hrs. 2-3 weeks thereafter, blasticidin resistant ES cell colonies 
(labeled miR-1-ES cells) were selected, expanded, and maintained in ES cell culture 
medium.  For control cells, a subset of CGR8 ES cells was transfected with the 
mammalian expression vector pTurboFP635-C (Evrogen) encoding RFP. 
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RNA Extraction and Real-time RT-PCR 
Total RNA was isolated from ES and miR-1-ES cells using RNA STAT-60 (Tel-
Test) and reverse transcribed using Taqman® MicroRNA Reverse Transcription Kit 
(Applied Biosystems) according to the manufacturer’s instructions.  Real-time RT-PCR 
was performed with specific miR-1 primers (Assay ID# 002222, Applied Biosystems) 
and Taqman® Universal PCR Master Mix (Applied Biosystems) using a CFX96™ Real-
Time System (Bio Rad).  Gene expression was normalized to U6 snRNA (Assay ID# 
001973, Applied Biosystems).  Data was analyzed and the miR-1 fold change 
calculated using the Bio Rad CFX Manager software (Version 1.6). 
MI and ES Cell Transplantation 
All mice were maintained and used as approved by the University of Central 
Florida animal review board.  8-10 week old C57BL/6 mice (Jackson laboratories) were 
divided into 4 study groups (n=8):  Sham, MI + cell culture media (MI + CC), MI + ES 
cells, and MI + miR-1-ES cells.  In brief, mice were anesthetized with 2.5% isoflurane, 
intubated, and ventilated using a rodent MiniVent (Harvard Apparatus).  Following a left 
thoracotomy, the left anterior descending (LAD) coronary artery was visualized and a 7-
0 ligature (CP Medical) was placed around the coronary artery.  Following LAD ligation, 
two separate intramyocardial injections of 10µl of media with or without 2.5 x 104 cells 
were delivered into the peri-infarct region.  The ribs, muscle, and skin were sutured, 
lungs expanded, and mice extubated following weaning from the ventilator.  Sham 
animals received all surgical procedures as detailed above excluding the LAD ligation. 
At D14 following surgery, mice were sacrificed with pentobarbital (80 mg/kg) followed by 
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cervical dislocation.  Hearts were removed, transversely cut, and fixed in formalin for 
further assessment. 
Immunohistochemistry 
Heart sections were deparaffinized and immunohistochemically stained using 
primary antibodies against RFP (for ES cells; AB232, Evrogen) or GFP (for miR-1-ES 
cells; A3122, Invitrogen) and sarcomeric α-actin (A2172, Santa Cruz).  Heart sections 
were then incubated with Alexa 488- or Alexa 568- conjugated secondary antibodies 
(Invitrogen), respectively.  Heart sections were washed and mounted with Anti-fade 
Vectashield mounting medium as mentioned above.  Co-localization of α−actin positive 
cells with GFP or RFP cells were counted as newly differentiated cells from transplanted 
donor cells in 1-2 sections from n=5-8 animals/group.  Sections were examined with 
Olympus and Leica TSC SP2 laser scanning confocal microscopes. 
Histopathology  
In brief, heart tissue was fixed in 4% buffered formalin, embedded in paraffin, and 
cut into 5 µm serial sections.  Embedded paraffin heart sections were placed onto 
Colorfrost Plus microscope slides (Fisher Scientific), deparaffinized, and rehydrated as 
previously reported(29). Thereafter, heart sections were stained with either hematoxylin 
and eosin (H&E) for teratoma evaluation or Mason’s trichrome for visualization of 
interstitial and vascular fibrosis.  Using NIH Image J software, interstitial fibrotic area 
was calculated by measuring the collagen-positive blue area (mm2) within the infarct, 
peri-infarct and non-infarct regions in 1-2 sections from 5-8 hearts/group.  Vascular 
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fibrosis was calculated as the ratio of vascular fibrosis to vessel area x 100% in 1-2 
sections from 5-8 hearts/group. 
TUNEL Staining 
TUNEL staining and analysis was performed as previously described by us and 
others(12; 15; 31; 32). In brief, heart sections were deparaffinized and permeabilized 
with proteinase K (25 μg/ml in 100 mM Tris·HCl).  An in situ apoptotic cell death 
detection kit (TMR red; Roche Applied Biosystems) was used to detect host 
myocardium apoptotic nuclei.  Heart sections were thereafter mounted with Anti-fade 
Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories) for nuclear visualization. Sections observed under Olympus and confocal 
microscopes.  The percentage of total apoptotic nuclei was determined in the infarct and 
peri-infarct regions from n=5-8 animals/group.  Percentage total apoptotic nuclei = (total 
number apoptotic nuclei) / (total number of DAPI) x 100%.   Heart sections were also 
stained with an anti-sarcomeric-α-actin antibody (A2172, Santa Cruz) to differentiate 
between apoptosis in cardiac myocytes and non-cardiac myocytes.  The percentage of 
cardiac myocyte apoptotic nuclei was calculated by (total number of red stained 
apoptotic nuclei co-localized with sarcomeric α-actin) / (total number of blue stained 
nuclei with DAPI) x 100%.   
Caspase-3 Activity Assay 
Caspase-3 activity assay was performed using a caspase-3 colorimetric activity 
assay kit from BioVision (K106-200).  Heart tissue was homogenized in 
radioimmunoprecipitation (RIPA) buffer containing protease inhibitors, 
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phenylmethylsulfonyl fluoride (PMSF), sodium orthovandate, and sodium fluoride. 
Homogenized heart tissue was centrifuged at 14,000 g for 5 min. Supernatant was 
removed and placed into fresh centrifuge tubes.  Protein concentration was estimated 
using a Bio Rad assay.  Caspase-3 activity was performed per the manufacturer’s 
instructions and color reaction was measured in a microtiter plate reader (Bio Rad) at 
405 nm.   Capsase-3 activity was plotted as arbitrary units (A.U.).  Data was collected 
from heart homogenates of n=6-8 animals/group in duplicates. 
DHE Staining 
Superoxide generation within infarcted myocardium was determined using 
dihydroethidium (DHE) fluorescence staining.  Following deparaffinization and 
hydration, heart sections were stained with 1µM/mL DHE for 25 minutes at room 
temperature.  The fluorescent images were captured on an Olympus and confocal 
microscope.  Using Image J, DHE fluorescence intensity was quantified in 4-5 randomly 
selected regions in the peri-infarct zone/section in 7-8 animals/group as previously 
reported (25). The average corrected integrated density (after background correction) 
was calculated for each group and DHE fluorescence intensity was plotted as arbitrary 
fluorescence units (A.F.U.).   
Akt Activity Assay 
p-Akt was quantitated using a phospho-Akt1 (PAN) ELISA kit (X1844k, Exalpha 
Biological) as detailed in the provided protocol.  In brief, hearts were homogenized and 
proteins were estimated as described above.  Samples were added to the wells 
containing captured antibodies provided in the kit and incubated with detector antibody, 
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HRP conjugate, substrate, and a stop solution with washings in between each step.  
The developed color reaction was measured in a microtiter plate reader (Bio Rad) at 
450 nm.  The values obtained from the ELISA were normalized to the total protein 
concentration for each sample as determined by the Bradford assay.  Phospho-Akt 
graph was plotted as arbitrary units.  Data was collected from heart homogenates of 
n=6-8 animals/group in duplicates. 
PTEN ELISA 
Phospho-PTEN (p-PTEN) was quantified using a Cell Signaling Technology® 
Phospho-PTEN Sandwich ELISA kit (#7285) as detailed in the instruction manual.  The 
developed reaction, proportional to the quantity of p-PTEN, was measured at 450 nm in 
a microtiter plate reader (Bio Rad).  ELISA results were corrected for the protein 
concentration of each tissue sample.  p-PTEN data was collected from heart 
homogenates from n=6-8 animals/group in duplicates and plotted as arbitrary units.    
MMP-9 Immunoassay 
MMP-9 concentration was determined by an enzyme-linked immunoassay 
(MMPT90, R&D Systems) as described by others and in the protocol provided with the 
kit(35; 40).  A color reaction, proportional to the amount of bound MMP-9, was 
measured in a microtiter plate reader (Bio Rad) at 450 nm.  Based on protein content of 
each sample, determined by Bradford assay, ELISA results were corrected.  MMP-9 
data was collected from heart homogenates from n=5-8 animals/group in duplicates and 
plotted as arbitrary units.    
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Echocardiography 
Cardiac function was assessed 2 wks post-MI by transthoracic 
echocardiography.  Mice were anesthetized with 2% inhalant isoflurane using a nose 
cone system and placed on a temperature controlled heating pad.  Echocardiography 
was performed using a Sonos 5500 Ultrasound system with a 15-6L hockey stick 
transducer.  Left ventricular internal dimension-diastole, left ventricular internal 
dimension-systole, fractional shortening (LVIDd-LVIDs/LVIDd x 100), and ejection 
fraction ((left ventricular volume at end diastole (EDV) – left ventricular volume at end 
systole (ESV))/EDV, EDV and ESV were calculated using the Teichholz formula(38)) 
were assessed in short axis view at the mid-papillary muscle level.   
Statistical Analysis 
All values presented as a mean ± standard error of the mean (SEM) and were 
analyzed using SigmaStat3.5 software.  Analysis of data was performed using the 
students’ t-test, one-way analysis of variance (ANOVA), and the Bonferroni test.  
Statistical significance was accepted for p<0.05.   
Results 
Figure 1A, a schematic representation showing pre-miR-1 oligonucleotide 
sequence and vector design used to overexpress miR-1 in ES cells (miR-1-ES cells).  
Following transfection, cells were selected and maintained in routine cell culture for 2-3 
wks.  RT-PCR performed on blasticidin-resistant colonies demonstrate more than a 
seven-fold increase in miR-1 expression in miR-1-ES cells compared to parental ES 
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cells (Figure 1B).  Additionally, Figure 1C (phase contrast) and 1D (green fluorescence) 
photomicrographs depict successful generation of miR-1-ES cells expressing GFP.      
miR-1 Enhances Cardiac Myocyte Differentiation  
 To assess whether miR-1 drives differentiation of transplanted ES cells into 
cardiac myocytes post-MI, heart sections were double immunolabeled for the cardiac 
myocyte marker α-actin and for GFP (miR-1-ES cells) or RFP (ES cells) to detect donor 
differentiated cells.  Co-localization of α-actin-positive cells with GFP or RFP positive 
cells were identified and counted as newly differentiated cardiac myocytes from donor 
ES cells.  Figures 2A-C show α-actin positive cardiac myocytes (red), 2D-F show 
transplanted donor cells (green), 2G-I show total nuclei stained with DAPI (blue), and 
2J-L show merged images of triple-labeled sections depicting cardiac myocyte 
differentiated from donor transplanted cells.  miR-1-ES cell transplanted hearts 
contained significantly more donor differentiated cells compared to ES cell and cell 
culture media transplanted hearts (mean ± SEM; MI + miR-1-ES cells: 38.33 ± 4.61 vs. 
MI + ES cells: 17.12 ± 2.23 and MI + CC: 0.00 ± 0.00, p<0.001, Figure 2E) suggesting 
miR-1 plays a major role in the differentiation of transplanted ES cells into cardiac 
myocytes post-MI.   
Transplanted miR-1-ES Cells Prevent Apoptosis in the Infarcted Heart 
TUNEL staining was performed and representative photomicrographs are 
depicted in Figure 3A-L.  At D14, there was a significant decrease in TUNEL-positive 
nuclei post-MI in miR-1 ES cell transplanted groups compared to ES cell and medium 
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groups (mean ± SEM; MI + miR-1 ES cells: 0.55 ± 0.06% vs. MI + ES cells: 0.87  ± 
0.05% and MI + CC: 1.45 ± 0.14% TUNEL positive nuclei/total nuclei, respectively, 
p<0.05, Figure 3Q).  Next, apoptosis in cardiac myocytes post-MI was determined in 
heart sections by co-labeling with sarcomeric α-actin (Figure 3M-P).  Our data reveals 
miR-1-ES cell transplanted hearts contained significantly fewer apoptotic cardiac 
myocyte nuclei compared to respective controls (p<0.05, Figure 3R).  To reinforce our 
TUNEL data, a caspase-3 activity assay was performed on heart homogenates from 5-8 
animals/group.  A significant decrease in caspase-3 activity in hearts transplanted with 
miR-1-ES cells post-MI compared to hearts transplanted with ES cells or medium alone 
resulted (p<0.05, Figure 3S). 
miR-1 Enhances p-Akt Activation in Post-MI Hearts 
Previous studies have identified direct and indirect mechanisms of apoptotic 
inhibition through activation of various cell survival cascades such as adenosine 
triphosphate-dependent tyrosine kinase (Akt)(33).  Using a phospho-Akt ELISA, we 
determined that hearts transplanted with miR-1-ES cells had significant activation of p-
Akt compared to hearts transplanted with ES cells and cell culture medium (mean ± 
SEM; MI + miR-1-ES cells: 6.88 ± 0.29, vs. MI + ES cells: 5.45 ± 0.14 and MI + CC 3.86 
± 0.59, p<0.05, Figure 4A).  To evaluate whether increased activation of p-Akt was 
attributable to inhibition of phosphoinositide-3-kinase (PI3K)/Akt signaling, levels of 
phosphatase and tensin homolog (PTEN), an inhibitor of PI3K phosphorylation, were 
quantified.  Our data illustrates a significant reduction in PTEN concentration in hearts 
transplanted with miR-1-ES cells vs. hearts transplanted with ES cells or cell culture 
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medium (mean ± SEM; MI + miR-1-ES cells: 6.49 ± 0.20, vs. MI + ES cells: 8.12 ± 0.44 
and MI + CC 10.08 ± 0.47, p<0.05, Figure 4B). 
Transplanted miR-1-ES Cells Reduce MI-Induced Oxidative Stress 
To examine the consequence of miR-1-ES cells on MI-induced oxidative stress, 
we analyzed intracellular superoxide anion production in heart sections using DHE 
fluorescent staining at D14 following MI or sham surgery.  As shown in the 
representative photomicrographs (Figure 5A-L) and summary data (Figure 5M), DHE 
staining was significantly reduced in miR-1-ES cell transplanted hearts compared with 
ES cell and cell culture medium transplanted hearts (mean ± SEM; MI + miR-1-ES cells: 
3.00 ± 0.53, vs. MI + ES cells: 6.08 ± 0.43 and MI + CC 11.37 ± 1.20, p<0.05, Figure 
5M).   
Effects of miR-1-ES Cells on Interstitial and Vascular Fibrosis  
 Heart sections were stained with Mason’s trichrome and interstitial fibrosis 
(Figure 6A-D) was quantified.  Quantitative analysis of trichrome stained heart sections 
indicated, compared to medium alone, both miR-1-ES cell and ES cell groups had a 
significant reduction in the amount of interstitial fibrosis (mean ± SEM; MI +CC: 1.02 ± 
0.06 mm2 vs. MI + miR-1-ES =cells: 0.36 ± 0.04 mm2 and MI + ES cells: 0.49 ± 0.03 
mm2, p<0.05, Figure 6I).  However, there was no statistical significance in interstitial 
fibrosis between miR-1-ES cell and ES cell groups.  Next, quantitative analysis of 
vascular fibrosis (Figure 6E-H) revealed miR-1-ES cell and ES cell transplanted hearts 
had a significant reduction in the amount of vascular fibrosis compared to hearts 
transplanted with cell culture medium (p<0.001, Figure 6J).  Again, as with interstitial 
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fibrosis, statistical significance was not reached between miR-1-ES cell and ES cell 
groups for vascular fibrosis.  
 Furthermore, matrix metalloproteinase-9 (MMP-9), a mediator of extracellular 
matrix (ECM) degradation and indicator of myocardial fibrosis post-MI, was quantified.  
miR-1-ES cell and ES cell transplanted hearts demonstrated significantly reduced MMP-
9 concentration compared with control hearts (p<0.01, Figure 6K).  However, as 
observed with interstitial and vascular fibrosis, there was no significant difference 
between miR-1-ES cell and ES cell groups. 
No Teratoma Formation in miR-1-ES Cell Transplanted Hearts 
ES cells have the capacity to differentiate into all derivatives of ectoderm, 
endoderm, and mesoderm, presenting the risk of teratoma formation at the injection 
site.  However, upon inspection of whole hearts and H&E stained heart sections, no 
teratoma formation was observed in any of the miR-1-ES cell or ES cell transplanted 
hearts (data not shown). 
Overexpression of miR-1 Improves Cardiac Function Post-MI 
 Echocardiography data showed mice receiving ES cell transplantation following 
MI had significantly improved fractional shortening compared to medium alone 
(p<0.001, Figure 7A).  Additionally, mice transplanted with miR-1-ES cells post-MI had 
significantly increased fractional shortening when compared to both ES cell and medium 
control groups (mean ± SEM; MI + miR-1-ES cells: 43.88 ± 0.33%, vs. MI + ES cells: 
40.53 ± 0.74% and MI + CC 32.33% ± 0.97%, p<0.01, Figure 7A).  Furthermore, miR-1-
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ES cell transplanted mice post-MI also had significantly improved ejection fraction when 
compared with mice transplanted with ES cells or medium post-MI (p<0.05, Figure 7B). 
Discussion 
The efficacy of cardiac myocyte differentiation from transplanted ES cells 
remains a major challenge to post-MI cell therapy. Numerous attempts have been made 
to enhance and drive cardiac myocyte differentiation from stem cells using various 
growth factors including bone morphogenetic protein-2 (BMP2), transforming growth 
factor β-2 (TGFβ−2) , vascular endothelial growth factor (VEGF), insulin-like growth 
factor-1 (IGF-1) and -2 (IGF-2), activin-A, fibroblast growth factor-2 (FGF-2) and -4 
(FGF-4), interleukin-6 (IL-6), and epidermal growth factor (EGF)(2; 34; 42; 45).  Despite 
these efforts, the observed donor cell differentiation into cardiac myocytes remains 
insufficient to regenerate the infarcted heart(8; 23).  Recently, miRs have been 
implicated in the differentiation of a myriad of cells types including epidermal cells, 
adipocytes, osteoblasts, neuronal cells, and cardiac muscle(11; 19-21; 43).  In the 
present study, we transfected ES cells with miR-1, a pro-cardiac microRNA, 
transplanted them into the myocardium post-MI, and evaluated their effects on cardiac 
myocyte differentiation, apoptosis, fibrosis, oxidative stress, and cardiac function. 
Our data for the first time suggest miR-1, when transfected in ES cells, following 
transplantation into the infarcted myocardium, significantly increases the amount of 
donor cell-derived differentiated cardiac myocytes compared with untransfected ES 
cells.  Our data corroborates with reports that miR-1 participates in early cardiac 
development in Drosophila and mice as well as enhances cardiac myocyte 
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differentiation in the cell culture system(19; 46; 47).  Although several miR-1 targets 
have been identified in the developing heart and cell culture system including histone 
deacetylase 4 (HDAC4), heart and neural crest derivatives-expressed protein 2 (Hand2) 
and cyclin-dependent kinase-9 (Cdk9)(6; 36; 39), the mechanisms by which miR-1 
transfected ES cells promote cardiac differentiation in the infarcted heart remains 
unknown. 
Next, it was imperative to investigate whether transplanted miR-1-ES cells 
promote additional repair mechanisms via inhibition of apoptosis and fibrosis in the 
infarcted myocardium.  In the current study, we report that transplanted miR-1-ES cells 
significantly reduce endogenous cardiac myocyte apoptotic cell death in the infarcted 
heart compared with untransfected ES cells. Our data is the first report demonstrating 
inhibition of cardiac myocyte cell death post-MI with transfected miR-1-ES cells. In 
contrast, several published reports have suggested that miR-1 is pro-apoptotic in 
cardiac myocytes following MI(26; 37).  However, the experimental design reported in 
the current study is completely distinct compared to the studies in which miR-1 is 
reported to be apoptotic which may explain the discrepancies between the varying 
results(26; 37).  Moreover, we are not the first group to report conflicting apoptotic data 
relative to miRs in various cell lines.  In fact, Wang recently concluded upon reviewing 
published data on miR-21 that a single miR has the potential to be apoptotic, anti-
apoptotic, or neutral depending on the cell line in which it is being expressed(41).   
In an attempt to elucidate mechanisms by which miR-1-ES cells inhibit host 
myocardium apoptosis post-MI, we investigated the connection between miR-1 and the 
PI3K/Akt pathway. The PI3K/Akt pathway is a well-documented signaling cascade 
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which controls regulation of various cellular processes including cell growth, 
proliferation, and survival.  Additionally, previous studies have demonstrated Akt to be 
cardioprotective and anti-apoptotic post-MI(13). To this end, we assessed the levels of 
activated Akt and were able to elucidate a positive correlation between Akt activation 
and apoptosis inhibition in miR-1-ES cell transplanted hearts.  Specifically, we noted 
that as apoptosis was significantly decreased in miR-1-ES cell transplanted hearts, 
levels of p-Akt were significantly increased compared to ES cell and cell culture medium 
transplanted hearts.  Although we were able to make this distinction, Akt mRNA is not a 
predicted target of miR-1.  To that end, we turned our investigation to upstream 
components of the Akt pathway. 
PTEN, an inhibitor of PI3K phosphorylation, blocks the subsequent activation and 
phosphorylation of Akt.  Therefore we could circumvent that down regulation of PTEN in 
the heart would result in increased PI3K/Akt signaling leading to restrained cardiac 
myocyte apoptosis and  inhibited maladaptive myocardial remodeling.  Our data was in 
corroboration with this line of thought as PTEN levels were significantly decreased in 
hearts transplanted with miR-1-ES cells compared to ES cell or cell culture medium 
transplanted hearts.  Although miR-1 is not predicted to target PTEN directly, negative 
regulation of PTEN activators may explain the increase in Akt activity and decrease in 
PTEN observed within this study.  However, because predicted targets of miR-1 span a 
myriad of mRNAs with a host of biological activities, determination of whether miR-1 
regulates these targets is beyond the scope of this study and requires further 
investigation.   
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Oxidative stress is a key mediator of myocardial apoptosis following MI(1; 30; 
33).  Oxidative stress-induced cardiac myocyte apoptosis involves the activation of 2 
independent pathways (Bcl-2 family activated mitochondrial intrinsic pathway and Fas 
ligand or TNF-α extrinsic pathway) through generated reactive oxygen species (ROS) 
including superoxide (O2•-), hydroxyl (OH•), hydrogen peroxide (H2O2), and peroxynitrite 
(ONOO-)(14).  Because miR-1 is not limited to single target regulation, we examined 
whether miR-1-ES cells also confer direct anti-apoptotic protective effects on infarcted 
myocardium through reactive oxygen species (ROS) attenuation.  Our data 
demonstrates that while MI induced the generation of superoxide in the myocardium, 
transplanted miR-1-ES cells blunted superoxide production.  Our study suggests that 
miR-1-ES cells may prevent apoptosis not only through activation of the cell-survival 
PI3K/Akt pathway, but also through regulation of ROS generation. 
In other respects, not only does adverse cardiac remodeling involve apoptosis 
but also the formation of fibrosis to rescue the architecture of the infarcted myocardium.  
Fibrosis formation involves the activation of metalloproteinases (MMPs), degradation of 
the extracellular matrix (ECM), and increased collagen deposition.  Previous studies 
have shown that stem cells following transplantation post-MI inhibit fibrosis 
formation(27; 29).  Although a trend of attenuated interstitial and vascular fibrosis was 
reported, our data shows that hearts transplanted with miR-1-ES cells post-MI 
demonstrate no significant additional decrease in fibrosis compared with untransfected 
ES cells.  MMP-9, a well-established mediator of ventricular remodeling, was also 
assessed to establish a relationship between miR-1-ES cells and blunted fibrosis.  
However, MMP-9 expression was not significantly diminished in miR-1-ES cell 
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transplanted hearts relative to ES cell transplanted hearts.  Our data indicates that 
although not significant, our miR-1-ES cells were able to parallel the anti-fibrotic effects 
of ES cells post-MI. 
  Finally, we needed to determine whether transplantation of miR-1-ES cells 
contribute to improved cardiac function following MI as the success of ES cell 
transplantation for post-MI therapy ultimately is defined by the improvement in cardiac 
contractility and output.  In the present study, we have demonstrated that 2 weeks 
following MI, mice transplanted with miR-1-ES cells had significantly increased 
fractional shortening and ejection fraction compared to mice transplanted with ES cells.  
Conceivably, enhanced cardiac myocyte differentiation from transplanted miR-1-ES 
cells within the infarcted myocardium resulting in attenuated adverse remodeling 
contributed to improved overall cardiac function. 
 In conclusion, we report that; 1) miR-1 promotes ES cell differentiation into 
cardiac myocytes in the infarcted heart, 2) miR-1-ES cells inhibit cardiac myocyte 
apoptosis, 3) inhibited apoptosis mediated by miR-1-ES cells involves the 
PI3K/PTEN/Akt pathway, 4) inhibited apoptosis is also associated with attenuated 
oxidative stress in miR-1-ES cell transplanted hearts, 5) miR-1-ES cells inhibit interstitial 
and vascular fibrosis relative to control MI, and 6) transplanted miR-1-ES cells post-MI 
improve cardiac function.   
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Figure 1. miR-1-ES cell generation.  A:  Diagram showing mouse pre-miR-1 oligonucleotide cloned into an expression 
vector.  GFP and miR-1 expression is driven by cytomegalovirus promoter.  B:  Histogram shows quantitative RT-PCR 
data demonstrating overexpression of miR-1 in miR-1-ES cells.  Representative photomicrographs of miR-1-ES cells in 





Figure 2. miR-1 enhances differentiation of ES cells into cardiac myocytes. Representative photomicrographs 
showing heart sections stained with anti-α-actin for cardiac myocytes (A-C), donor transplanted cells (D-F), nuclei stained 
with DAPI (G-I), and the merged image (J-L) showing co-expression of α-actin and GFP/RFP indicating differentiated 
donor cells.  M: Histogram shows quantitative analysis of differentiated donor ES cells into cardiac myocytes 2 wks 





Figure 3. Effects of transplanted ES cells overexpressing miR-1 on host cardiac myocyte apoptosis in C57BL/6 
mice.  Representative photomicrographs of total nuclei stained with DAPI in blue (A-D), apoptotic nuclei stained with 
TUNEL in red (E-H), and merged nuclei in pink (I-L).  Magnification, 40X.  Scale bar = 50 µm.  Top right panel (M-P), 
representative photomicrographs of section labeled with sarcomeric α-actin in green (M), TUNEL in red (N), DAPI in blue 
(O), and merged image (P) demonstrating apoptosis occurs within cardiac myocytes.  Magnification, 40X.  Boxed area 
below panel P enlarged to show co-localization of sarcomeric α-actin, TUNEL, and DAPI.  Bottom left panel (Q), 
histogram shows quantitative total apoptotic nuclei.  *p<0.001 vs. MI + CC, #p<0.05 vs. MI + ES cells and MI + CC.  Data 
set are from 1-2 sections from n=5-8 hearts/group.  Bottom middle panel (R), histogram shows a significant decrease in 
cardiac myocyte apoptosis in miR-1-ES cell group.  *p<0.01 vs. MI + CC, #p<0.05 vs. MI + ES cells and MI + CC.  Data 
set are from 1-2 sections from n=5-8 hearts/group.  Bottom right panel (S), histogram shows quantitative decreases in 
caspase-3 activity in MI + miR-1-ES cells compared with MI + ES cells and MI + CC.  *p<0.01 vs. MI + CC, #p<0.05 vs. MI 






Figure 4. miR-1 mediates anti-apoptotic effects through modulation of the PTEN/Akt pathway.  A:  Histogram 
reveals significant increase in p-Akt activity in hearts transplanted with miR-1-ES cells.  *p<0.05 vs. MI + CC, #p<0.05 vs. 
MI + ES cells and MI + CC.  Data set are from heart homogenates of n=6-8 animals/group.  B:  Histogram show 
quantitative decrease in PTEN expression in hearts following transplantation of miR-1-ES cells.  *p<0.05 vs. MI + CC, 
#p<0.05 vs. MI + ES cells and MI + CC.  Data set are from heart homogenates of n=5-8 animals/group in duplicates.  A.U. 







Figure 5. miR-1-ES cells attenuate oxidative stress in the infarcted myocardium.  Left panel (A-L), representative 
photomicrographs of DAPI in blue (A-D), DHE in red (E-H), and merged images (I-L) demonstrating a significant decrease 
in superoxide production in hearts transplanted with miR-1-ES cells.  Magnification, 40X.  Right panel (M), histogram 
shows quantitative analysis of DHE staining.   *p<0.001 vs. MI + CC, #p<0.05 vs. MI + ES cells and MI + CC.  Data set 






Figure 6. Effects of transplanted ES cells overexpressing miR-1 on vascular and interstitial fibrosis.  
Representative photomicrographs from sections stained with Mason’s trichrome 2 wks following coronary artery ligation 
from each group demonstrating interstitial (A-D) and vascular (E-H) fibrosis.  Magnification, 40X.  Bottom left panel (I), 
histogram shows quantitative interstitial fibrosis.  *p<0.001 vs. MI + CC.  Data set are from 1-2 sections from n=6-8 
hearts/group.  Bottom middle panel (J), histogram shows quantitative analysis of vascular fibrosis in heart sections after 2 
wks of coronary artery ligation. *p<0.001 vs. MI + CC. VA= vessel area, VF=vessel fibrosis.  Data set are 1-2 sections 
from n=6-8 hearts/group.  Bottom right panel (K), histogram shows quantitative MMP-9 expression significantly decreased 
in miR-1-ES cell and ES cell groups.   *p<0.01 vs. MI + CC. Data set are from heart homogenates of n=5-8 animals/group 







Figure 7. Transplanted miR-1-ES cells improve cardiac function in C57BL/6 mice following MI.  Echocardiography 
was performed D14 following MI.  A:  Histogram shows average fractional shortening at 2 wks post-MI for all treatment 
groups.  *p<0.001 vs. MI + CC, #p<0.01 vs. MI + ES cells and MI + CC.  Data set are from n=8 animals/group.  B:  
Histogram shows transplanted miR-1-ES cells significantly improve fractional shortening.  *p<0.001 vs. MI + CC, #p<0.05 
vs. MI + ES cells and MI + CC.  Data set are from n=5-8 animals/group. 
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CHAPTER THREE: ES CELLS OVEREXPRESSING microRNA-1 ATTENUATE 
APOPTOSIS IN THE INJURED MYOCARDIUM  
Abstract 
MicroRNAs (miRs) are small, single-stranded, non-coding RNA’s involved in 
post-transcriptional negative gene regulation.  Recent investigations have underscored 
the integral role of miRs in various biological processes including innate immunity, cell-
cycle regulation, metabolism, differentiation, and cell death.  In the present study, we 
overexpressed miR-1, a muscle-specific miR, in embryonic stem cells (miR-1-ES cells), 
transplanted them into the infarcted myocardium, and evaluated their impact on cardiac 
apoptosis and function.  We provide evidence demonstrating reduced apoptosis 
following transplantation of miR-1-ES cells 4 weeks post-myocardial infarction as 
compared to respective controls assessed by TUNEL staining and a capsase-3 activity 
assay.  Moreover, we show significant elevation in p-Akt levels and diminished PTEN 
levels in hearts transplanted with miR-1-ES cells as determined by enzyme-linked 
immunoassays.  Finally, using echocardiography, we reveal mice receiving miR-1-ES 
cell transplantation post-myocardial infarction had significantly improved fractional 
shortening and ejection fraction compared with respective controls. Our data suggest 
transplanted miR-1-ES cells inhibit apoptosis, mediated through the PTEN/Akt pathway, 
leading to improved cardiac function in the infarcted myocardium.   
Introduction 
Myocardial infarction (MI) induces cardiac myocyte cell death triggering left 
ventricular remodeling leading to hypertrophy, fibrosis, and dysfunction(3; 21).  
Apoptosis, programmed cell death, is responsible for millions of cardiac myocytes lost 
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following MI and subsequent ventricular remodeling (3; 7).  Taking into account cardiac 
myocytes are mostly terminally differentiated with minimal potential for cell division and 
the limited number of cardiac progenitor stem cells, intrinsic cardiac muscle 
regeneration is not sufficient to restore the heart to pre-MI homeostasis(15; 27).  Given 
this, the challenge to develop effective therapies which protect the host myocardium 
from apoptosis following MI remains ever present.       
Recent investigations have identified miRs as regulators of countless processes 
including cellular development, differentiation, metabolism, and death(4; 6; 9; 11). miRs 
are small, single stranded, non-coding RNAs which negatively influence gene 
expression through post-transcriptional modifications. miR manipulation to gain 
therapeutic effects for the treatment of various physiological and pathological conditions 
has gained notable attention within the research community. 
 Recently reported, miR-1 is a pro-cardiac miR which has been shown to enhance 
cardiac myocyte differentiation in the cell culture system(4; 28).  Whether miR-1-
overexpressing embryonic stem (ES) cells following transplantation into the infarcted 
myocardium can inhibit apoptosis 4 weeks post-MI requires investigation.  Therefore, 
we postulate that miR-1 will act as an anti-apoptotic miR when overexpressed in 
transplanted ES cells post-MI.  Our data suggests that miR-1 over expressing ES cells 
following transplantation into the infarcted myocardium reduce total apoptotic nuclei.  
Furthermore, the observed decrease in apoptosis is mediated through up regulation of 
the Akt pathway and down regulation of PTEN in miR-1-ES cell transplanted hearts.  
Finally, we illustrate that in vivo delivery of miR-1-ES cells 4 weeks post-MI improves 
cardiac function. 
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Materials and Methods 
ES Cell Culture 
Mouse CGR8 ES cells were passaged and maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) containing 15% ES-qualified FBS, leukemia inhibitory factor 
(LIF), glutamine, non-essential amino acids, penicillin/streptomycin, β-mercaptoethanol, 
and sodium pyruvate as previously described(23). 
miR-1-ES Cell Generation  
Pre-miR-1 oligonucleotides (5’-tgc tgT GGA ATG TAA AGA AGT ATG Tag ttt tgg 
cca ctg act gac TAC ATA CTT TTA CAT TCC A-3’ and 5’-cct gTG GAA TGT AAA AGT 
ATG Tag tca gtc agt ggc caa aac TAC ATA CTT CTT TAC ATT CCA c-3’) were cloned 
into an expression vector (pcDNA 6.2-GW/EmGFP, Invitrogen).  48 hrs post-
transfection into mouse CGR8 ES cells using Lipofectamine 2000 (Invitrogen), media 
was changed and selection media containing 2 µg/ml blasticidin (Invitrogen) was added 
and changed every 48 hrs thereafter for 2-3 weeks. Blasticidin resistant ES cell colonies 
(labeled miR-1-ES cells) were passaged and maintained in ES cell culture medium as 
described beforehand.  The miR-1-ES cell cloning strategy is part of another submitted 
paper (Glass and Singla, unpublished data).  
RNA Extraction and real-time RT-PCR 
Total RNA was extracted using RNA STAT-60 (Tel-Test).  cDNA synthesis was 
performed with Taqman® MicroRNA Reverse Transcription Kit (Applied Biosystems) 
according to the manufacturer’s protocol.  Specific primers (Assay ID# 002222, Applied 
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Biosystems) and Taqman® Universal PCR Master Mix (Applied Biosystems) were used 
for amplification and identification of miR-1.  Real-time RT-PCR was performed using a 
CFX96™ Real-Time System (Bio Rad).  The relative amount of miR-1 was normalized 
against U6 snRNA (Assay ID# 001973, Applied Biosystems) and the fold change for 
miR-1 was calculated. 
MI and ES Cell Transplantation 
All experimental procedures were performed on 8-10 week old C57BL/6 mice 
(Jackson laboratories) and were approved by the University of Central Florida animal 
review board.  Male and female mice were divided into 4 study groups (n=8):  Sham, MI 
+ cell culture media (MI + CC), MI + ES cells, and MI + miR-1-ES cells.  In brief, mice 
were intubated, ventilated using a rodent MiniVent (Harvard Apparatus), and 
anesthetized with 2.5% inhalant isoflurane throughout the procedure.  Following a left 
thoracotomy, a permanent ligature was placed around the coronary artery.  The peri-
infarct region was identified and two separate intramyocardial injections totaling 20µl of 
media with or without 5.0 x 104 cells were delivered using a 29-gauge floating needle.  
After suturing the ribs, muscle, and skin, the lungs were expanded and mice were 
extubated.  Sham animals received identical surgical procedures as detailed above 
while omitting the ligation. At D28 following surgery, mice were sacrificed using 
pentobarbital (80 mg/kg, ip) followed by cervical dislocation.  Hearts were removed, 
transversely cut, and fixed in 4% paraformaldehyde for further analyses. 
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TUNEL Staining 
Heart tissue fixed in 4% buffered formalin was embedded in paraffin, cut into 
serial sections (5 µm), and placed onto Colorfrost Plus slides (Fisher Scientific).  TUNEL 
staining and analysis was performed as we previously reported(24; 25). In brief, 
deparaffinized heart sections were permeabilized with proteinase K (25 μg/ml in 100 
mM Tris·HCl) and an in situ apoptotic cell death detection kit (TMR red; Roche Applied 
Biosystems) was used to identify apoptotic nuclei within the infarcted myocardium as 
per the manufacturer’s instructions.  Thereafter, heart sections were mounted with Anti-
fade Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI; 
Vector Laboratories). Sections were observed under Olympus fluorescent and confocal 
microscopes.  The percentage of apoptotic nuclei was determined in the infarct and 
peri-infarct regions of heart tissue from n=5-8 animals/group.  Percentage total apoptotic 
nuclei = (total number apoptotic nuclei) / (total number of DAPI) x 100%.    
Caspase-3 Activity Assay 
Caspase-3 activity was quantitated using a caspase-3 colorimetric activity assay 
kit from BioVision (K106-200).  Heart tissue was homogenized in RIPA buffer containing 
phenylmethylsulfonyl fluoride, sodium orthovandate, protease inhibitor cocktail, and 
sodium fluoride. Following centrifugation, supernatant was removed and protein 
concentration was estimated for each sample using the Bradford assay.  Caspase-3 
activity assay was performed following the manufacturer’s instructions included with the 
kit.  The resulting ODs at 405 nm were normalized to the protein concentration of each 
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sample and plotted as arbitrary units (A.U.).  Data was collected from heart 
homogenates of n=5-8 animals/group in duplicates. 
p-Akt Activity Assay 
p-Akt was quantified in heart homogenates using a phospho-Akt1 (PAN) ELISA 
kit (X1844k, Exalpha Biological) as detailed in the provided instructions.  The developed 
color reaction was measured at 450 nm and the values obtained from the ELISA were 
normalized to the total protein concentration for each sample.  Data was collected from 
heart homogenates of n=5-8 animals/group in duplicates. 
PTEN ELISA 
Phospho-PTEN (p-PTEN) was quantitated using a Phospho-PTEN Sandwich 
ELISA kit (#7285) from Cell Signaling Technology® as detailed in the provided manual.  
The developed color reaction was measured at 450 nm and results were corrected for 
the protein concentration of each tissue sample.  p-PTEN data was obtained from heart 
homogenates of n=5-8 animals/group in duplicates and plotted as A.U.    
Echocardiography 
Cardiac function was assessed 4 weeks post-MI by non-invasive transthoracic 
echocardiography in short axis view at the mid-papillary muscle level using a Sonos 
5500 Ultrasound system as we reported previously(25).  Obtained measurements 
include left ventricular internal dimension-diastole (LVIDd), left ventricular internal 
dimension-systole (LVIDs), fractional shortening (FS), and ejection fraction (EF).   
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Statistical Analysis 
Data are presented as a mean ± SEM.  Statistical analysis of data was 
performed using the one-way analysis of variance (ANOVA) and the Bonferroni test.  
p<0.05 was considered statistically significant.   
Results 
Following transfection of ES cells with our generated miR-1 expression vector, 
blasticidin resistant cells were selected and maintained in cell culture for 2-3 weeks.  To 
determine miR-1 expression in miR-1-ES cells and parental ES cells, RT-PCR was 
performed.  Our data demonstrates more than a seven-fold increase in mature miR-1 
expression in miR-1-ES cells compared to parental ES cells (Figure 8).     
Transplanted miR-1-ES Cells Inhibit Apoptosis Post-MI 
To assess apoptosis within the infarcted myocardium, TUNEL staining was 
performed and representative photomicrographs are depicted in Figure 9A-L.  At day 28 
(D28), there was a significant decrease in TUNEL-positive nuclei post-MI in miR-1 ES 
cell transplanted hearts compared to ES cell and medium transplanted hearts (p<0.05, 
Figure 9M).  To support our TUNEL data, caspase-3 activity was quantified and a 
significant decrease in hearts transplanted with miR-1-ES cells post-MI compared to 
hearts transplanted with ES cells or medium alone resulted (p<0.05, Figure 10). 
miR-1 Enhances p-Akt Activation and Inhibits PTEN Post-MI  
Several mechanisms of apoptosis inhibition through various cell survival 
cascades have been reported including activation of the Akt pathway(26).  To 
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quantitatively assess phospho-Akt (p-Akt), we performed an ELISA and were able to 
circumvent hearts transplanted with miR-1-ES cells had significant p-Akt activation 
compared to hearts transplanted with ES cells and cell culture medium (p<0.05, Figure 
11A).  To evaluate whether enhanced p-Akt was consequent to inhibition of negative 
regulators of Akt activation, levels of PTEN, an antagonist of the Akt pathway, were 
quantitated.  Our data demonstrates a significant reduction in PTEN in the miR-1-ES 
cell group vs. the ES cell or cell culture medium group (p<0.01, Figure 11B). 
Transplanted miR-1-ES Cells Improve Cardiac Function Post-MI 
 Our echocardiography data at D28 illustrates mice receiving miR-1-ES cell 
transplantation following MI had significantly improved fractional shortening compared 
to ES cell and cell culture controls (mean ± SEM; MI + miR-1-ES cells: 44.73 ± 0.72, vs. 
MI + ES cells: 39.51 ± 1.02 and MI + CC 31.15 ± 1.69, p<0.05, Figure 12A).  
Additionally, miR-1-ES cell transplanted mice post-MI also had significantly improved 
ejection fraction when compared with controls post-MI (mean ± SEM; MI + miR-1-ES 
cells: 76.79 ± 0.86, vs. MI + ES cells: 70.46 ± 1.37 and MI + CC 61.36 ± 2.39, p<0.05, 
Figure 12B). 
Discussion 
 Apoptosis, characterized by cell blebbing and shrinkage, chromatin 
condensation, and DNA fragmentation, plays an integral role in the pathogenesis of 
various cardiovascular diseases including MI(8).  Cardiac myocyte apoptosis following 
MI is a highly orchestrated programmed cell death initiated through various stressors 
including cytokines, oxidative stress, and DNA damage(1; 7; 8).  Although a multitude of 
63 
attempts have been made to attenuate apoptosis in the infarcted myocardium through 
the use of various stem cell populations and genetic modifications, apoptosis remains a 
key factor in the adverse outcomes of MI(5; 10; 12; 14; 22).  
In this study, we reveal a novel role of miR-1, when over expressed in ES cells, 
in the regulation of cardiac myocyte apoptosis in the infarcted myocardium.  We 
illustrate miR-1-ES cells inhibit host myocardium apoptosis 4 weeks post-MI.  
Conversely, recent investigations have reported that in the infarcted myocardium, miR-1 
promotes apoptosis in cardiac myocytes(20; 29).  However, the difference between the 
conflicting results lies within the cell type in which miR-1 is being expressed; that is, 
miR-1 has been shown to be apoptotic in endogenous cardiac cell types whereas we 
are suggesting miR-1 is anti-apoptotic when miR-1 over expressing ES cells are 
transplanted into the infarcted heart(29).  Noticeably, these studies are unique from one 
another and demonstrate varying results.  Nevertheless, this is not the first conflicting 
report in regards to the apoptotic nature of a particular miR.  Consistent with our 
findings, it has been recently suggested that miRs can possess apoptotic, anti-
apoptotic, or neither characteristic based solely on the type of cell in which they are 
being expressed(30).  These conclusions underscore the importance of defining the 
apoptotic function of a distinct miR to a specific cell type.  
We next wanted to define mechanisms by which transplanted miR-1-ES cells 
obviate host myocardium apoptosis post-MI.   Previous studies have identified the 
involvement of the Akt pathway in the regulation of cell growth, metabolism, 
proliferation, and survival(17; 26). Moreover, the Akt pathway has been implicated in 
cardioprotection and apoptosis inhibition following MI through various secreted 
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paracrine factors including secreted fizzled related protein 2 and follistatin-like 1(2; 13; 
16).  We evaluated the levels of activated Akt and noted a negative correlation between 
Akt activation and apoptosis inhibition.  Specifically, we were able to illustrate a 
significant increase in p-Akt paralleled by a significant decrease in apoptosis in miR-1-
ES cell transplanted hearts compared to controls suggesting our data is in accordance 
with these previously published studies(2; 26).  We propose that increased Akt 
expression observed within the miR-1-ES cell transplanted hearts leads to the observed 
cardioprotective effects through increased secreted paracrine factors.  However, 
identification of exact paracrine mediators responsible for inhibited apoptosis is well 
beyond the scope of the current study and will require further investigation.   
We next explored the potential effects of transplanted miR-1-ES cells on PTEN, 
an Akt signaling cascade inhibitor.  We hypothesized that down regulation of PTEN 
might account for the up regulation of p-Akt observed in the miR-1-ES cell transplanted 
hearts.  We were able to elucidate that levels of PTEN were, in fact, significantly 
decreased in hearts transplanted with miR-1-ES cells compared to control hearts.  
Although PTEN is not a predicted mRNA target of miR-1, further investigation may 
determine whether miR-1 down regulates PTEN activators thus explaining the 
increased Akt activity and decreased PTEN observed within this study.  In fact, a recent 
publication demonstrated a mechanistic correlation between miR-101 and activation of 
Akt through down regulation of MAGI-2, a PTEN activator, as we suggest within the 
present study for miR-1(19). 
  Lastly, we tested how inhibition of apoptosis by transplanted miR-1-ES cells 
would impact cardiac function 4 weeks following MI.  In vivo delivery of miR-1-ES cells 
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significantly increased fractional shortening and ejection fraction post-MI compared to 
respective controls.  Conceivably, we suggest that inhibited apoptosis within the 
infarcted myocardium through miR-1 overexpression in transplanted ES cells obviated 
subsequent remodeling events post-MI leading to improved cardiac function.  Our data 
is in agreement with a previously published study suggesting in vivo delivery of miR-24 
into the mouse infarcted heart suppressed apoptosis thus attenuating contractility 
loss(18). 
Next our data suggest that the observed beneficial effects in the present study 
may not be the direct effects of released miR-1 from overexpressing ES cells on 
reduced apoptosis.  Rather, it may involve various factors released from transplanted 
miR-1-ES cells.  Therefore, transplantation of LNA-miR-1 directly into the infarcted heart 
in comparison with the overexpressing miR-1-ES cells may further shed light on the 
mechanisms of reduced apoptosis in this model. 
 In summary, we report that transplanted miR-1-ES cells inhibit apoptosis in the 
infarcted heart and these effects are mediated through the PTEN/Akt pathway.  
Furthermore, we illustrate the capability of transplanted miR-1-ES cells to improve 
cardiac function 4 weeks post-MI.  Our data suggests the potential therapeutic 
applications using miR-1 modulation for the treatment of apoptosis-induced cardiac 
conditions.  However, to determine how miR-1 exerts its anti-apoptotic effects in 
infarcted myocardium when overexpressed in ES cells, further studies are required to 
determine which mRNA targets are directly regulated by miR-1. 
66 
Acknowledgements 
This work was supported in part from grants from the National Institutes of Health 






Figure 8. miR-1 overexpression confirmed by RT-PCR.  Histogram shows quantitative RT-PCR data demonstrating 







Figure 9. Transplanted miR-1-ES cells inhibit apoptosis.  Representative photomicrographs of DAPI in blue (A-J), 
apoptotic nuclei in red (B-K), and merged nuclei in pink (C-L).  Magnification, 40X.  Right histogram (M) shows 






Figure 10. miR-1-ES cells inhibit caspase-3 activity in the infarcted myocardium.   Histogram shows significant 
decreases in caspase-3 activity in MI + miR-1-ES cells compared with MI + ES cells and MI + CC.  *p<0.001 vs. MI + 







Figure 11. miR-1-ES cells exert apoptosis inhibition through PTEN/Akt pathway.  Left histogram (A) reveals 
significant increase in p-Akt activity in hearts transplanted with miR-1-ES cells.  *p<0.001 vs. MI + CC, #p<0.05 vs. MI 
+ ES cells and MI + CC.  Right histogram (B) show quantitative PTEN expression.  *p<0.05 vs. MI + CC, #p<0.01 vs. 







Figure 12. Transplanted miR-1-ES cells improve cardiac function four weeks following MI.  Echocardiography 
was performed at four weeks following MI.  Left histogram (A) shows average fractional shortening for all treatment 
groups.  *p<0.001 vs. MI + CC, #p<0.05 vs. MI + ES cells and MI + CC.  Right histogram (B) shows transplanted miR-
1-ES cells significantly improve fractional shortening.  *p<0.01 vs. MI + CC, #p<0.05 vs. MI + ES cells and MI + CC. 
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CHAPTER FOUR: OVEREXPRESSION OF TIMP-1 IN EMBRYONIC STEM CELLS 
ATTENUATES ADVERSE CARDIAC REMODELING FOLLOWING MYOCARDIAL 
INFARCTION  
Abstract 
 Transplanted embryonic stem (ES) cells following myocardial infarction (MI) 
contribute to limited cardiac repair and regeneration with improved function.  Therefore, 
novel strategies are still needed to understand the effects of genetically modified 
transplanted stem cells on cardiac remodeling.  The present study evaluates whether 
transplanted ES cells overexpressing TIMP-1, an anti-apoptotic and anti-fibrotic protein, 
can inhibit native cardiac myocyte apoptosis, reduce fibrosis, and enhance cardiac 
function in the infarcted myocardium.  MI was produced in C57BL/6 mice by coronary 
artery ligation.  TIMP-1-ES cells, ES cells, or culture medium (control) was transplanted 
into the peri-infarct region of the heart.  Immunofluorescence, TUNEL staining, caspase-
3 activity, histology, and echocardiography were used to assess apoptosis, fibrosis, and 
heart function.  Hearts transplanted with TIMP-1-ES cells demonstrated a reduction in 
apoptosis as well as an increase (p<0.05) in p-Akt activity compared with ES cells or 
culture media controls.  Interstitial and vascular fibrosis was significantly (p<0.05) 
decreased in the TIMP-1-ES cell group compared to controls.  Furthermore, MMP-9, a 
key pro-fibrotic protein, was significantly (p<0.01) reduced following TIMP-1-ES cells 
transplantation. Echocardiography data showed fractional shortening and ejection 
fraction were significantly (p<0.05) improved in the TIMP-1-ES cell group compared with 
respective controls.  Our data suggest that transplanted ES cells overexpressing TIMP-
1 attenuate adverse myocardial remodeling and improve cardiac function compared 
with ES cells which may have therapeutic potential in regenerative medicine. 
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Introduction 
Cell transplantation strategies using renewable sources of cardiac myocytes to 
repair damaged myocardium, replace lost cardiac cells, and prevent remodeling 
following MI has gained significant attention.  We, as well as others, have shown that 
transplanted embryonic stem (ES) cells post-MI have the potential to engraft, 
differentiate into cardiac-specific cell types, limit adverse myocardial remodeling, and 
improve heart function(3; 9; 22; 23).  However, inhibition of adverse cardiac remodeling 
following cell transplantation is minimal relative to normal heart architecture and overall 
cardiac function.  Therefore, novel approaches are needed to augment the efficacy by 
which transplanted ES cells enhance cardiac repair in order to optimize cardiac regain-
of-function following cell transplantation therapy. 
Following MI, ventricular architectural remodeling consequent to myocardial 
infarction (MI) is characterized by various physiological and cellular changes including 
cardiac cell death via apoptosis and necrosis, fibrosis, and hypertrophy leading to end 
stage heart failure(2; 10; 13; 18; 23).  In response to myocardial cell death post-MI, 
increased expression of extracellular matrix (ECM) proteins, specifically collagen type I 
and III, occurs evoking fibrosis formation(16; 28). Fibrosis within the injured myocardium 
causes stiffening of the heart and overall systolic and diastolic dysfunction. Matrix 
metalloproteinases (MMPs) are a family of endopeptidases which play a fundamental 
role in the degradation and aberrant production of ECM proteins leading to alterations in 
ventricular architect post-MI.  Tissue inhibitors of metalloproteinases (TIMPs) are innate 
protease inhibitors of MMPs.  TIMP-1, the most extensively characterized TIMP, is not 
only a well-documented anti-fibrotic protein(4; 5; 7), but also has recently been shown to 
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exhibit anti-apoptotic characteristics in non-cardiac cell types such as breast epithelial 
cells (15; 24; 31).  Moreover, we were the first to report that TIMP-1 is a cytoprotective 
released factor from ES cells which prevents H2O2-induced apoptosis in vitro in 
cardiomyoblasts (H9c2 cells)(24).  However, whether TIMP-1, when overexpressed in 
transplanted ES cells, can impact adverse cardiac remodeling post-MI by blunting host 
myocardium apoptosis and fibrosis has yet to be delineated. 
 In the present study, we hypothesize that ES cells overexpressing TIMP-1 
(TIMP-1-ES cells) following transplantation into the infarcted myocardium will attenuate 
apoptosis and fibrosis along with improve cardiac function.  To accomplish this 
hypothesis, we generated ES cells overexpressing TIMP-1 (TIMP-1-ES cells), 
transplanted them into the infarcted myocardium, and evaluated their impact on 
apoptosis, fibrosis, and associated cardiac function.  Our data shows that transplanted 
TIMP-1-ES cells post-MI significantly inhibit cardiac myocyte apoptosis compared with 
ES cells and the anti-apoptotic effect of TIMP-1 is, in part, mediated through the Akt 
pathway.  Furthermore, we demonstrate that transplanted TIMP-1-ES cells inhibit both 
interstitial and vascular fibrosis in the infarcted myocardium.  Finally, we show that 
transplantation of TIMP-1-ES cells post-MI significantly enhances cardiac function.   
Materials and Methods 
ES Cell Culture 
CGR8 ES cells with or without TIMP-1 were cultured and maintained on 0.1 % 
gelatin-coated tissue culture plates in Dulbecco’s minimum essential medium (DMEM) 
growth media supplemented with leukemia inhibitory factor (LIF), sodium pyruvate, 
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glutamine, penicillin/streptomycin, non-essential amino acids, β-mercaptoethanol, and 
15% ES qualified fetal bovine serum as we previously reported(27). 
TIMP-1-ES Cell Generation 
The mammalian expression vector (pTurboFP635-C) encoding red fluorescent 
protein (RFP) was purchased from Evrogen (Moscow, Russia).  The cDNAs coding 
mouse TIMP-1 gene were generated by PCR cloning using high fidelity DNA 
polymerase and PCR primers (forward: 5’-AGAGCAGATACCATGATG-3’ and reverse: 
5’-GAAGGCTTCAGGTCATCG-3’).  The PCR product was cloned to the Bgl II and 
BamH l site of the pTurboFP635 C-terminus as a single open reading frame.  The 
expression vector contained a neomycin-resistance gene for selection of stable 
transfectants in CGR8 ES cell lines.  The sequence of mouse TIMP-1 gene was 
confirmed by restriction enzyme digestion and DNA sequencing analysis.   
CGR8 mouse ES cells were transfected with the TIMP-1 expression vector using 
Lipofectamine 2000 (Invitrogen).  Selection media containing 100 µg/ml G418 
(Invitrogen) was added 48 hrs post-transfection.  Selection media was changed every 
48 hrs and cells were maintained for 2-3 weeks. Thereafter, G418 resistant ES cell 
colonies (labeled TIMP-1-ES cells) were selected, expanded, and maintained in ES cell 
culture medium.  TIMP-1-ES cell clones were confirmed with elevated TIMP-1 protein 
expression as compared to parental CGR8 ES cells through western blot analysis using 
a primary antibody against TIMP-1 (sc-5538, Santa Cruz) following by incubation with 
goat anti-rabbit IgG secondary antibody (sc-2004, Santa Cruz).   
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MI and ES Cell Transplantation 
All mice were maintained and used as approved by the institutional animal review 
board.  C57BL/6 mice (8-10 weeks old) were divided into 4 study groups (n=8 per 
group):  Sham, MI + cell culture media (MI + CC), MI + ES cells, and MI + TIMP-1-ES 
cells.  In brief, mice were anesthetized, endotracheally intubated, and ventilated using a 
rodent MiniVent (Harvard Apparatus).  Anesthesia was maintained using 2.5% 
isoflurane throughout the procedure.  Left thoracotomy was performed and the 
descending left coronary artery was ligated as we reported previously(12).  Following 
ligation, two intramyocardial injections of 10µl of medium containing 2.5X104 TIMP-1-ES 
cells or ES cells was delivered into the peri-infarct region.  The chest was then closed, 
lungs expanded, and mice were weaned from the ventilator and extubated.  Sham 
group animals received all identical surgical procedures with the exception of no 
coronary artery ligation. Mice received postoperative care, including analgesia 
(buprenorphine, 0.5 mg/kg), for 2 days or until normal behavior resumed.  Two weeks 
following surgery, mice were sacrificed by pentobarbital (80 mg/kg) followed by cervical 
dislocation.  Hearts were removed, transversely cut, and fixed in 4% paraformaldehyde 
for further evaluation. 
Histopathology  
Heart tissue was embedded and sectioned as previously described(23).  In brief, 
heart tissue was embedded in paraffin blocks, cut in serial sections (5 µm), and placed 
onto Colorfrost Plus microscope slides (Fisher Scientific).  Heart sections were 
deparaffinized using room temperature xylene followed by sequential incubation in 100, 
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95, and 70% ethanol for 3 minutes and washed with distilled water.  Heart sections were 
then stained with Mason’s trichrome.  To quantify interstitial fibrosis, infarct, peri-infarct, 
and non-infarct regions of the heart were examined and fibrosis was quantified by 
measuring the total blue area/total heart area x 100%.  Vascular fibrosis was quantified 
by measuring vascular fibrosis/vessel area x 100% in 1-2 sections from 5-8 
hearts/group.  All fibrosis measurements were made using NIH image J software. 
TUNEL and Cardiac α-Actin Staining  
TUNEL staining was performed as previously described(25). In brief, heart 
sections were deparaffinized and permeabilized with proteinase K (25 µg/ml in 100 mM 
Tris·HCl).  The TUNEL assay kit (TMR red; Roche Applied Biosystems) was used as 
per the manufacturer’s instructions to detected host myocardium apoptotic nuclei.  
Apoptotic cells were co-labeled with cardiac α-actin (A2172, Sigma) to detected 
apoptosis within cardiac myocytes.  Heart sections were then mounted with Antifade 
Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories) for nuclear staining and observed under Olympus and confocal 
microscopes.  Percentage total apoptotic nuclei = (total number of red stained apoptotic 
nuclei) / (total number of blue stained nuclei with DAPI) x 100.   Additionally, the 
percentage of apoptotic nuclei in cardiac myocytes was also determined by (total 
number of red stained apoptotic nuclei co-localized with sarcomeric α-actin) / (total 
number of blue stained nuclei with DAPI) x 100. Total apoptotic nuclei and apoptotic 
cardiac myocyte nuclei were quantitated in the infarct and peri-infarct regions of the 
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heart in 1-2 sections from 5-8 hearts from each group.  These cell counts were 
performed as previously reported by us and others(6; 8; 26). 
Caspase-3 Activity Assay 
Caspase-3 activity was quantitated using a caspase-3 colorimetric activity assay 
kit (K106-200, BioVision).  Hearts were homogenized in RIPA buffer containing 
protease inhibitor cocktail (Sigma), phenylmethylsulfonyl fluoride (PMSF) (1mM), 
sodium orthovandate (2mM), and sodium fluoride (5mM), collected, and centrifuged at 
11766 rpms for 5 min.  The supernatant was removed and protein concentration 
estimation was performed using a Bio Rad assay.  Manufacturer’s instructions were 
followed to complete the activity assay.  Developed blue color was measured in a 
microtiter plate reader (Bio Rad) at 405 nm.  Caspase-3 activity graph was plotted as 
arbitrary units (A.U.).     
Phosphorylated Akt Activity Assay 
Phosphorylated Akt (p-Akt) was quantitated using a phospho-Akt1 (PAN) ELISA 
kit (X1844k, Exalpha Biological) as previously described and detailed in the instruction 
manual provided with the kit(26).  In brief, hearts were homogenized and proteins were 
estimated by the Bradford method.  Samples (25 µl) and sample diluents (75 µl) were 
added to the wells labeled with captured antibodies provided in the kit for 2 hrs.  
Following washing, samples were incubated with detector antibody for 2 hrs, HRP 
conjugate for 30 mins, and substrate for 30 mins with washings in between each step.  
A stop solution was added and developed yellow color was measured in a microtiter 
plate reader (Bio Rad) at 450 nm.  Phospho-Akt graph was plotted as detailed in the kit. 
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MMP-9 Immunoassay 
MMP-9 concentration was determined by an enzyme-linked immunoassay 
(MMPT90, R&D Systems).  In brief, hearts from n=8 animals/group were homogenized 
and protein concentrations were estimated as aforementioned.  Samples were loaded 
into monoclonal MMP-9 immobilized antibody-coated wells provided in the kit for 2 hrs.  
Following washings, a conjugate (polyclonal antibody for mouse MMP-9) was added for 
an additional 2 hrs.  Again the wells were washed and a substrate solution was added 
to each well for 30 minutes followed by the addition of a stop solution.  A color reaction 
developed proportional to the amount of bound MMP-9 and was measured in a 
microtiter plate reader (Bio Rad) at 450 nm.  MMP-9 graph was plotted as arbitrary units 
(A.U.).  
Echocardiography 
Cardiac function for all mice groups was assessed non-invasively by 
transthoracic echocardiography at D14.  Mice were anesthetized with 2% isoflurane, 
placed and maintained on a temperature controlled heating pad, and the chest was 
shaved.  Echocardiography was performed using a Phillips Sonos 5500 Ultrasound 
system with a 15-6L hockey stick transducer.  Left ventricular internal dimension-
diastole (LVIDd), left ventricular internal dimension-systole (LVIDs), fractional 
shortening (LVIDd-LVIDs/LVIDd x 100), and ejection fraction ((left ventricular volume at 
end diastole (EDV) – left ventricular volume at end systole (ESV))/EDV, EDV and ESV 
were calculated using the Teichholz formula(29)) were determined at the mid-papillary 
muscle level in short axis view. 
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Statistical Analysis 
All values presented as a mean ± SEM.  Statistical analysis was performed using 
the students’ t-test, one-way analysis of variance (ANOVA), and the Bonferroni test.  
Statistical significance was assigned when p < 0.05.   
Results 
To elucidate the impact of TIMP-1 in transplanted ES cells post-MI on cardiac 
remodeling and function, we overexpressed TIMP-1 (Figure 13A-C) in CGR8 ES cells.  
Following selection with G418, TIMP-1-ES cells were maintained in cell culture for 10-
12 weeks.  To determine stable transfection, western blot analysis was performed and 
our data shows significantly increased TIMP-1 expression compared to parental ES 
cells (p<0.001, Figure 13D).  
Transplanted TIMP-1-ES Cells Prevent Apoptosis in the Infarcted Heart 
 To determine whether transplanted ES cells overexpressing TIMP-1 inhibit 
apoptosis compared to ES cells in the host myocardium, TUNEL staining was 
performed (Figure 14A-L).  At D14, there was a significant decrease in TUNEL-positive 
nuclei post-MI in the infarct and peri-infarct regions of hearts transplanted with ES cells 
compared to controls (Figure 14Q, p<0.001).  Moreover, TIMP-1-ES cell transplanted 
hearts contained significantly fewer total apoptotic nuclei compared to ES cell and cell 
culture medium groups (mean ± SE; MI + TIMP-1-ES cells: 0.63 ± 0.06% vs. MI + ES 
cells: 0.94 ± 0.07% and MI + CC: 1.55 ± 0.12%, TUNEL positive/total nuclei, p<0.05, 
Figure 14Q). Additionally, heart sections were colabeled with sarcomeric α-actin to 
demonstrate and quantitate apoptosis within cardiac myocyte nuclei (Figure 14M-P).  
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Our data shows apoptotic cardiac myocyte nuclei were significantly reduced in hearts 
transplanted with TIMP-1-ES cells compared with ES cell and media transplanted 
hearts (p<0.05, Figure 14R). Next, to strengthen our TUNEL data, a caspase-3 
colorimetric assay was performed on heart homogenates from each group.   There was 
a significant decrease in caspase-3 activity in hearts treated with TIMP-1-ES cells post-
MI compared to hearts transplanted with ES cells or medium alone (mean ± SE; MI + 
TIMP-1-ES cells: 171.75 ± 2.56 vs. MI + ES cells: 188.50 ± 1.80 and MI + CC: 203.00 ± 
4.36, p<0.05, Figure 14S). 
TIMP-1 Enhances p-Akt Activation in Post-MI Hearts 
Previous studies have shown that mechanisms of inhibited apoptosis involve the 
activation of cell-survival pathways including p-Akt (27).  Our data demonstrates that 
hearts transplanted with TIMP-1-ES cells did in fact have significant increase in the 
activation of p-Akt compared to hearts transplanted with ES cells and medium (mean ± 
SE; MI + TIMP-1-ES cells: 6.99 ± 0.22, vs. MI + ES cells: 5.75 ± 0.16 and MI + CC 4.61 
± 0.25, p<0.05, Figure 15), suggesting up-regulation of cell survival pathways.  
Reduced Fibrosis Following MI in TIMP-1-ES Cell Group 
 To quantify the amount of cardiac fibrosis, heart sections were stained with 
Masson’s trichrome.   Interstitial fibrosis in the infarcted heart sections was measured at 
D14 and representative photomicrographs from each group are depicted in Figure 16A-
D.  Compared to medium alone, ES cell transplanted hearts had a significant reduction 
in the amount of total interstitial fibrosis (Figure 16, right panel histogram, p<0.01). 
Furthermore, the reduced interstitial fibrosis observed in TIMP-1-ES cell transplanted 
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hearts was significant when compared to ES cell and control hearts (mean ± SE; MI + 
TIMP-1-ES cell: 0.23 ± 0.03 mm2 vs. MI + ES cells: 0.47 ± 0.02 mm2 and MI +CC: 0.90 
± 0.00 mm2, p<0.01, Figure 16E).  
To determine whether inhibition of fibrosis was associated with changes in MMP-
9, a well-documented MMP involved in the pathogenesis of MI, MMP-9 was quantified 
using an enzyme-linked immunoassay.  Hearts transplanted with ES cells demonstrated 
significantly reduced MMP-9 concentration compared with control hearts (p<0.01, 
Figure 16F).  Moreover, MMP-9 concentration within TIMP-1-ES cell transplanted hearts 
was significantly less compared to hearts transplanted with ES cells or media (mean ± 
SE; MI + TIMP-1-ES cells: 21.19 ± 1.27 vs. MI + ES cells: 41.64 ± 3.83 and MI + CC: 
63.81 ± 8.18, p<0.01, Figure 16F). 
Next, quantitative assessment of vascular fibrosis (Figure 17A-D) revealed ES 
cell transplanted hearts had a significant decrease in the amount of vascular fibrosis 
compared to medium alone (p<0.001, Figure 17, right panel histogram).  Furthermore, 
the attenuation of vascular fibrosis in TIMP-1-ES cell transplanted hearts reached 
statistical significance when compared to ES cells (p<0.05, Figure 17, right panel 
histogram). 
Overexpression of TIMP-1 Improves Cardiac Function Post-MI 
 Cardiac function data assessed by echocardiography at D14 suggests mice 
receiving ES cell transplantation following MI had significantly improved fractional 
shortening compared to medium alone (p<0.001, Figure 18A).  Mice transplanted with 
TIMP-1-ES cells post-MI had significantly increased cardiac function when compared to 
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mice transplanted with ES cells and medium post-MI at D14 (mean ± SE; MI + TIMP-1-
ES cells: 44.81 ± 0.70% vs. MI +ES cells: 41.01 ± 0.61% and MI + CC: 31.30 ± 0.88%, 
p<0.05, Figure 18A).  Furthermore, our ejection fraction data demonstrates mice 
transplanted with TIMP-1-ES cells had significantly enhanced ejection fraction when 
compared with ES cell or control groups (p<0.05, Figure 18B).   
Discussion 
Many stem cell types examined thus far including skeletal myoblasts, bone 
marrow stem cells, bone marrow-derived hematopoietic stem cells, endogenous cardiac 
stem cells, mesenchymal stem cells, induced pluripotent stem (iPS) cells, and ES cells 
have shown improved cardiac function following transplantation post-MI(11; 19-22).  
Improvement in cardiac function in past studies was demonstrated by newly 
differentiated cardiac myocytes and inhibition of apoptosis and fibrosis.  However, 
observed effects of stem cell transplantation following MI was not enough to provide 
complete protection required to reestablish normal heart function.  Therefore new 
strategies, such as modulation of ES cells using anti-apoptotic and anti-fibrotic genes, 
are required.  In the present study, we transfected ES cells with TIMP-1, an anti-
apoptotic and anti-fibrotic gene, transplanted them into the myocardium post-MI, and 
evaluated their effects on myocardial remodeling (apoptosis and fibrosis) and cardiac 
function. 
Apoptosis is a major mechanism by which cardiac myocyte cell death occurs 
following MI leading to hypertrophy, fibrosis and ultimately, poor cardiac function.  
TIMP-1, an intrinsic cardiac glycoprotein which plays a role in MMP inhibition and 
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mitogenic modulation, has recently been identified as anti-apoptotic in various cell lines 
including human osteosarcoma cells (MG-63), mouse bone marrow stromal cells (MBA-
1), murine MC3T3-E1 osteoblasts, human breast epithelial cells, and rat 
cardiomyoblasts (H9c2)(17; 24; 30; 31). The present study demonstrates a significant 
reduction in apoptosis in the host myocardium following transplantation with TIMP-1-ES 
cells compared to ES cells confirmed by TUNEL staining and caspase-3 activity assay.  
Our data is in accordance with a previously published study suggesting TIMP-1 
conditioned media (CM) prevents H2O2-induced apoptosis in an in vitro model similar to 
ischemic myocardium(24).  
Previous studies have reported a positive correlation between TIMP-1 and 
activation of the Akt signaling cascade promoting breast epithelial and UT-7 erythroid 
cell survival(1; 14).  Our present study also provides evidence indicating hearts 
transplanted with TIMP-1-ES cells had significant activation of p-Akt compared to hearts 
transplanted with ES cells and medium controls.  Although future detailed studies are 
necessitated to determine the exact mechanisms of the TIMP-1 anti-apoptotic influence, 
our findings are in corroboration with previous studies suggesting  mechanisms of 
inhibited apoptosis involve the activation of cell-survival pathways including Akt(27).   
 Fibrosis, a major contributor to adverse cardiac remodeling, is consequent to 
increased MMP activation post-MI which leads to ECM degradation, increased collagen 
deposition, stiffening of the heart, and ultimately, poor cardiac function.  In the present 
study, our cardiac fibrosis data (interstitial and vascular fibrosis) demonstrates 
significantly reduced fibrosis in hearts treated with TIMP-1-ES cells compared with 
hearts transplanted with ES cells.  Additionally, hearts transplanted with TIMP-1-ES 
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cells contained significantly less MMP-9 compared with ES cell and CC groups post-MI.  
Following an MI, increased MMP activation is not paralleled by an increase in TIMP-1 
expression(32).   Therefore, we suggest significant reduction in the post-MI fibrosis 
observed in the TIMP-1-ES cell transplanted hearts compared to ES cell transplanted 
hearts may be attributable to inhibition of MMP-9 through overexpression of TIMP-1.  
However, further studies are required to define these mechanisms.   
Finally, we needed to determine whether inhibition of apoptosis and fibrosis in 
the host myocardium contribute to improved cardiac function following MI in TIMP-1-ES 
cell transplanted animals.  In the present study, our data demonstrates that 2 weeks 
following MI, mice transplanted with TIMP-1-ES cells had significantly increased 
fractional shortening and ejection fraction compared to mice transplanted with ES cells 
or cell culture medium.  Overall, our findings indicate that transplantation of TIMP-1-ES 
cells attenuate adverse cardiac remodeling and improve heart function following MI.       
 In conclusion, the major findings of the present study relative to ES cells include; 
1) TIMP-1-ES cells significantly inhibit cardiac apoptosis in the infarcted myocardium, 2) 
inhibition of apoptosis in hearts transplanted with TIMP-1-ES cells is mediated, in part, 
through the Akt pathway, 3) transplanted TIMP-1-ES cells significantly inhibit interstitial 
and vascular fibrosis as well as the pro-fibrotic protein, MMP-9, following MI, and 4) 
transplanted TIMP-1-ES cells significantly improve overall cardiac function following MI 
through retention of functional cardiac myocytes and  maintenance of the integrity of the 
host myocardium.  However, future studies are required to identify further detailed 
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Figure 13. TIMP-1 vector and the generation of TIMP-1-ES cells.  A:  TIMP-1 cDNA was cloned into the 
pTurboFP635-C expression vector encoding RFP.  TIMP-1-ES cells were selected following incubation with G418.  
Representative photomicrographs of TIMP-1-ES cells in bright field microscopy (B) and under fluorescence 
microscopy (C) to demonstrate RFP expression.  D:  Representative photomicrographs of western blot. Histogram 






Figure 14. Effects of transplanted ES cells overexpressing TIMP-1 on host cardiac myocyte apoptosis in 
C57BL/6 mice. ES and TIMP-1-ES cells were transplanted post-MI and hearts were examined for apoptosis 2 wks 
following cell transplantation.  Representative photomicrographs of total nuclei stained with DAPI in blue (A-D), 
apoptotic nuclei stained with TUNEL in red (E-H), and merged nuclei in pink (I-L).  Magnification, 40X.  Top right panel 
(M-P),  set of representative photomicrographs of section labeled with sarcomeric α-actin (M), apoptotic nuclei stained 
with TUNEL in red (N), total nuclei stained with DAPI in blue (O), and merged image (P) demonstrating apoptosis 
occurs within the cardiac myocyte.  Magnification, 40X.  Boxed area in panel O enlarged to show colocalization of 
sarcomeric α-actin, TUNEL positive nucleus, and DAPI. Bottom left histogram (Q) shows total apoptotic nuclei in the 
infarct and peri-infarct regions of the heart in 1-2 sections from 5-8 hearts from each group.  *p<0.001 vs. MI + CC, #p 
<0.05 vs. MI + CC and MI + ES cells.  Bottom middle histogram (R) shows quantitative cardiac myocyte apoptotic 
data.  *p<0.01 vs. MI + CC, #p<0.05 vs. MI + CC and MI + ES cells.   Bottom right histogram (S) shows quantitative 
analysis of caspase-3 activity in hearts transplanted with and without stem cells.  *p<0.05 vs. MI + CC, #p<0.05 vs. MI 






Figure 15. Phospho-Akt activation enhanced in TIMP-1-ES cell transplanted hearts.  Histogram shows 
quantitative analysis of phospho-Akt activation.  *p<0.01 vs. MI + CC, #p<0.01 vs. MI + CC and MI + ES cells.  Data 







Figure 16. Effects of transplanted ES cells overexpressing TIMP-1 on interstitial fibrosis.  Representative 
photomicrographs from sections stained with Masson’s trichrome 2 wks following coronary artery ligation from each 
group (A-D).  Magnification, 20X.  E:  Histogram shows quantitative total interstitial fibrosis per section.  *p<0.01 vs. MI 
+ CC, #p<0.05 vs. MI + CC and MI + ES cells.  Data sets are from 1-2 sections from 5-8 hearts/group.  F:  Histogram 
shows average MMP-9 concentration within hearts from n=5-8 animals per group.  *p<0.01 vs. MI + CC, #p<0.05 vs. 







Figure 17. Transplanted TIMP-1-ES cells inhibit vascular fibrosis following MI.  Representative photomicrographs 
of large vessels stained with Masson’s trichrome 2 wks post-MI to demonstrate vascular fibrosis (A-D).  Right panel:  
Histogram representing quantitative analysis of vascular fibrosis in heart sections. *p<0.001 vs. MI + CC, #p<0.01 vs. 








Figure 18. TIMP-1 overexpressed in ES cells improves cardiac function in C57BL/6 mice.  Echocardiography 
was performed D14 following MI and fractional shortening and ejection fraction was quantified.  A:  Average fractional 
shortening at 2 wks post-MI for all treatment groups.  *p<0.001 vs. MI + CC, #p<0.05 vs. MI + CC and MI + ES cells.   
FS=fractional shortening.  B:  Histogram shows quantified average ejection fraction.  *p<0.001 vs. MI + CC, #p<0.05 
vs. MI + CC and MI + ES cells. Data set are from n=8 different animals/group.   
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CHAPTER FIVE: DISCUSSION 
Although previous investigations have demonstrated inhibited cardiac remodeling 
and improved cardiac function following ES cell transplantation into experimental 
infarcted myocardium, results are modest(4; 7; 16; 23).  The general consensus among 
researchers suggests refinement and optimization of stem cell populations are 
necessary to transcend stem cell therapy from concept to actuality for use in the clinical 
arena(28; 30).  Tremendous efforts are now underway to enhance the efficacy by which 
ES cells differentiate into cardiac cell types following transplantation and inhibit 
apoptosis and fibrosis in the infarcted myocardium.  In this regard, we generated ES 
cells overexpressing miR-1, a pro-cardiac microRNA, and TIMP-1, an anti-apoptotic and 
anti-fibrotic gene, transplanted them into the peri-infarct region post-MI, and evaluated 
their effects on engraftment, differentiation, and myocardial remodeling. 
We suggest, for the first time, generated ES cells overexpressing miR-1, 
following transplantation into the infarcted myocardium, demonstrate dramatically 
increased donor cell-derived differentiated cardiac myocytes compared with 
transplanted, untransfected ES cells.  Our in vivo data authenticates previous reports 
indicating miR-1 plays an integral role in early cardiac development in Drosophila and 
mice as well as mediates cardiac myocyte differentiation in vitro(13; 35; 36).  Numerous 
studies have identified specific miR-1 targets involved in early cardiac organogenesis, 
including histone deacetylase 4 (HDAC4), heart and neural crest derivatives-expressed 
protein 2 (Hand2), notch ligand delta-like 1 (Dll-1) and cyclin-dependent kinase-9 (Cdk9) 
(5; 6; 12; 26).  To understand and delineate mechanism by which miR-1 drives cardiac 
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myocyte differentiation from transplanted ES cells in the infarcted myocardium will 
require future investigation.   
Next, it was pertinent to investigate whether transplanted miR-1-ES cells promote 
additional repair mechanisms (apoptosis and fibrosis inhibition) in the injured 
myocardium.  In the first study (Chapter 2), we report that inhibition of apoptotic cell 
death is significantly different in miR-1-ES and ES cell transplanted hearts compared to 
cell culture medium controls.  Notably, we demonstrate a significant reduction in intrinsic 
cardiac myocyte apoptotic cell death in miR-1-ES cell transplanted hearts compared to 
hearts transplanted with ES cells.  Our data is the first report suggesting endogenous 
cardiac myocyte apoptosis inhibition is mediated by miR-1.  Conversely, previous 
studies have concluded miR-1 mediates apoptosis in cardiac myocytes by post-
transcriptional repression of HSP60, HSP70, caspase-9, IGF-1 and Bcl2(22; 27; 33).  
However, the experimental design in our study (miR-1 expression in ES cells) and the 
studies by which miR-1 is pro-apoptotic (miR-1 expression in cardiac myocytes) are 
vastly unique which may explain the discrepancies between these studies.  Previous 
research has concluded that miR-1 expression increases in neonatal hearts and 
substantially abundant levels are maintained in the adult heart(33).  However, miR-1 is 
not abundantly expressed in ES cells as we have demonstrated with our RT-PCR data.  
Therefore we suggest that the behavior of miR-1 within ES cells (anti-apoptotic) may be 
uniquely different than that in cardiac myocytes (pro-apoptotic) by targeting different 
mRNAs found in each cell type.  Indeed, upon a review of published miR-21 data, Wang 
et al suggested that the behavior of a miR can and does vary based on the cell line in 
which it is being expressed(31). 
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To elucidate mechanisms of miR-1-mediated apoptosis inhibition in the infarcted 
myocardium, we investigated the relationship of miR-1 and the PI3K/Akt pathway.  The 
PI3K/Akt signaling pathway is involved in a host of biological activities including cell 
survival, growth, and proliferation.  Phosphorylated and activated Akt promotes cell 
survival by phosphorylating and activating downstream anti-apoptotic substrates and by 
phosphorylating and inactivating pro-apoptotic substrates.  Akt has been shown to be a 
key player promoting cardioprotection and anti-apoptotic regulation in the ischemic 
myocardium(10).  More so, previous studies have shown an up-regulation of activated 
p-Akt following cell transplantation in the post-MI heart(25).  We assessed the levels of 
activated Akt and revealed a positive correlation between p-Akt and apoptosis inhibition.  
Notably, as apoptosis was dramatically decreased in miR-1-ES cell transplanted hearts, 
p-Akt expression was significantly increased compared with ES cell and CC 
transplanted hearts.  Importantly, we suggest that the decreased adverse remodeling 
observed within our study using transplanted miR-1-ES cells is partially consequent to 
increased p-Akt expression.  Previous studies have shown that Akt-mediated paracrine 
factors including secreted frizzled related protein 2 and follistatin-like 1 promote survival 
and repair of the injured myocardium(17; 19).  We suggest that increased Akt 
expression observed within the miR-1-ES cell transplanted hearts leads to the observed 
cardioprotective effects through increased secreted paracrine factors.  Using miR 
mRNA target prediction websites (targetscan.org and microrna.org), we were able to 
conclude that Akt mRNA is not a predicted miR-1 target as we did not expect it to be.  
To that end, we turned our attention to upstream modulators of the PI3K/Akt pathway to 
identify a link between miR-1 and up-regulated activated Akt. 
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PTEN inhibits the PI3K/Akt pathway by dephosphorylating PIP3 and 
subsequently blocking the phosphorylation and activation of Akt.  We hypothesized that 
down-regulation of PTEN would lead to increased levels of p-Akt as observed within our 
study.  We assessed levels of PTEN and were able to conclude that levels of PTEN 
were in fact significantly decreased in hearts transplanted with miR-1-ES cells 
compared with respective controls.  Using bioinformatics, we were also able to 
extrapolate miR-1 does not directly target PTEN mRNA.  However, we hypothesize that 
miR-1 may down regulate activators of PTEN thus leading to increased activated Akt 
expression within miR-1-ES cell transplanted hearts.  In fact, there was a recent 
publication demonstrating a mechanistic relationship between miR-101 and activation of 
Akt through down regulation of a PTEN activator as we suggest within our study for 
miR-1(21).  However, because miR-1 is not limited to single target regulation, 
determination of the miR-1 target mRNAs responsible for the inhibition of apoptosis is 
well beyond the scope of Study 1 and will require further investigation. 
As stated previously, the vast predicted mRNA targets for miR-1 span a host of 
biological activities.  Therefore, we examined whether miR-1 could also confer 
cardioprotection to the injured myocardium through inhibition of oxidative stress.  
Oxidative stress has been shown to play a key role in myocardial apoptosis and 
subsequent adverse remodeling following MI(2; 24).  We were able to demonstrate that 
transplantation of miR-1-ES cells following MI significantly inhibited superoxide anion 
production.  Our study suggests that miR-1-ES cells protect the host myocardium from 
MI-induced apoptosis not only through activation of the Akt pathway, but also through 
inhibition of oxidative stress.   
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In other respects, we investigated the role of transplanted miR-1-ES cells on 
fibrosis formation post-MI as adverse remodeling involves the production of excess 
fibrous connective proteins to rescue the infarcted ventricular geometry.  Interstitial and 
vascular fibrosis was dramatically decreased in hearts transplanted with ES and miR-1-
ES cells compared with controls.  However, statistical significance was not attained in 
fibrosis inhibition between ES and miR-1-ES cell groups.  MMP-9, a mediator of fibrosis 
in the infarcted heart, was also quantified to verify our fibrosis results.  Our data 
demonstrates that although significant to cell culture medium controls, there was no 
significant reduction in MMP-9 expression in hearts transplanted with ES and miR-1-ES 
cells supporting our quantitative interstitial and vascular fibrosis data. 
Finally, in Study 1, we needed to determine whether enhanced cardiac myocyte 
differentiation of transplanted miR-ES cells and inhibited apoptosis contributed to 
improved cardiac function as the success of stem cell transplantation ultimately is 
defined by the improvement in left ventricular contractility and output.  Previous studies 
have revealed improved cardiac function following transplantation of various stem cell 
populations in the infarcted heart(9; 16; 18; 23).  We demonstrate that 2 weeks following 
MI, fractional shortening and ejection fraction are significantly improved in miR-1-ES cell 
transplanted mice compared to ES cell transplanted mice.  Conceivably, we suggest 
that enhanced cardiac myocyte differentiation from transplanted miR-1-ES cells and 
inhibition of myocardial apoptosis contribute to the improved left ventricular function. 
Study 2 (Chapter 3) was undertaken to assess the role of miR-1 and apoptosis 
inhibition in a chronic model of MI.  Apoptosis accounts for millions of cardiac myocytes 
lost following MI(2).  Research has shown that apoptosis not only occurs in hours but 
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also months following ischemia suggesting apoptosis plays a role in remodeling and the 
development of heart failure(1).  Given this, the challenge to generate effective 
therapies which will protect the host myocardium from apoptosis at short and long term 
following MI remains ever present.  In Study 1, we were able to demonstrate the anti-
apoptotic effects of miR-1 overexpressing ES cells following transplantation into the 
injured myocardium in an acute setting of MI.  Whether miR-1 overexpressing ES cells 
following transplantation in the infarcted myocardium could inhibit apoptosis 4 weeks 
post-MI was unknown. 
Evidences provided in Study 2 demonstrate a novel role of miR-1 in the 
regulation of host myocardium apoptosis 4 weeks following MI.  We reveal that 
apoptosis, assessed by TUNEL staining and a caspase-3 activity assay, was 
significantly reduced in hearts transplanted with miR-1-ES cells compared with controls 
suggesting the anti-apoptotic effects of miR-1 were long lasting.  We further assessed 
whether mechanisms by which miR-1 obviates apoptosis in the acute model of MI were 
similar to those at 4 weeks post-MI.  As observed in Study 1, levels of p-Akt were 
significantly improved in the miR-1 group compared with the ES cell and cell culture 
media groups.  We also quantified levels of PTEN and revealed that at 4 weeks post-MI, 
PTEN expression was dramatically decreased compared with respective controls.  Our 
data suggest that mechanisms of inhibited apoptosis by miR-1-ES cells in the chronic 
model of MI are similar to those in an acute model of MI. 
Finally, we wanted to investigate the impact of apoptosis inhibition by miR-1-ES 
cells on cardiac function at 4 weeks following MI.  In vivo delivery of miR-1-ES cells 
significantly improved fractional shortening and ejection fraction 4 weeks following 
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transplantation and MI.  Our data is in corroboration with a previously published study 
demonstrating  in vivo delivery of miR-24 suppressed apoptosis in the injured 
myocardium leading to improved contractile function(20).   Our data from Study 2 
suggests that miR-1, when overexpressed in transplanted ES cells, has the capacity to 
inhibit apoptosis long term while attenuating contractility loss. 
In Study 1, the goal was to enhance cardiac myocyte differentiation from 
transplanted ES cells using miR-1 which addresses one of the major issues of current 
stem cell therapy.  In an attempt to address the issue of limited adverse remodeling 
inhibition, we overexpressed TIMP-1, an intrinsic cardiac glycoprotein, in ES cells in 
Study 3 (Chapter 4).  TIMP-1, an anti-fibrotic protein which modulates MMP activation 
and mitogenic regulation, has recently been shown to exhibit anti-apoptotic 
characteristics in various cell lines including human osteosarcoma cells, mouse bone 
marrow stromal cells, murine osteoblasts, human breast epithelial cells, and rat 
cardiomyoblasts(15; 24; 29; 32).  In Study 3, we were able to show that myocardial 
apoptosis was significantly decreased in hearts transplanted with TIMP-1-ES cells 
compared to hearts transplanted with ES cells or cell culture media.  Our data 
corroborates our previously published in vitro data suggesting TIMP-1 inhibits H2O2 
induced apoptosis in cardiomyoblasts. 
Along the same line of thought in Study 1, we wanted to see if a relationship 
existed between transplantation of TIMP-1-ES cells and activation of the PI3K/Akt 
pathway to explain the significant inhibition of apoptosis.  Previous studies in breast 
epithelial and erythroid cells had demonstrated an association between TIMP-1 and cell 
survival through activation of the PI3K/Akt pathway(3; 14).  Our data suggests p-Akt 
120 
expression was significantly increased in hearts transplanted with TIMP-1-ES cells 
compared with ES and cell culture medium controls.  Although the precise mechanism 
detailing the role of TIMP-1 in apoptosis inhibition has not been elucidated, we suggest 
TIMP-1 perpetuates its anti-apoptotic influence through activation of the PI3K/Akt 
pathway. 
 Fibrosis, a chief component of adverse cardiac remodeling, involves increased 
MMP activation post-MI which leads to ECM degradation, increased collagen 
deposition, stiffening of the heart, and ultimately, poor cardiac function.  TIMP-1 is well 
established as an endogenous inhibitor of MMPs by binding the active site of secreted 
and membrane bound pro-MMPs  preventing cleavage of the pro-peptide domain and 
subsequent activation(8; 11).  However, following an MI, increased MMP activation is 
not paralleled with increased TIMP-1 expression(34).  Therefore, we hypothesized that 
TIMP-1when overexpressed in transplanted ES cells in the post-MI heart would 
significantly inhibit cardiac fibrosis through inhibition of MMP activation.  Our data 
substantiates our hypothesis as interstitial and vascular fibrosis was significantly 
decreased in hearts transplanted with TIMP-1-ES cells compared to large fibrotic areas 
in cell culture media transplanted hearts.  Additionally, expression levels of MMP-9, a 
pivotal MMP in cardiac fibrosis post-MI, were significantly decreased in TIMP-1-ES cell 
groups compared with ES cell and cell culture medium controls.  We suggest that TIMP-
1, when overexpressed in transplanted ES cells post-MI, exerts its anti-fibrotic influence 
through inhibition of MMP-9 activation and consequential ECM degradation and 
increased ECM protein production. 
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Finally, in Study 3, we wanted to determine if inhibition of maladaptive left 
ventricular remodeling by transplanted TIMP-1-ES cells sufficed to improve contractile 
function of the infarcted myocardium.  Our functional data reveals that mice 
transplanted with TIMP-1-ES cells post-MI had significantly improved fractional 
shortening and ejection fraction compared to mice receiving ES cells or cell culture 
media.  We suggest that the dramatic improvement in cardiac function in hearts 
transplanted with TIMP-1-ES cells is consequent to inhibition of host myocardial 
apoptosis and fibrosis. 
Conclusions drawn from Study 1, 2, and 3 include: 1) miR-1 promotes cardiac 
myocyte differentiation of transplanted ES cells in the infarcted myocardium, 2) miR-1-
ES cells suppress apoptosis in the acute setting of MI, 3) inhibited apoptosis mediated 
by miR-1-ES cells involves activation of Akt and down-regulation of PTEN, 4) reduced 
apoptosis following transplantation of miR-1-ES cells is also mediated though 
attenuation of ROS, 5) miR-1-ES cells inhibit interstitial and vascular fibrosis relative to 
control MI, 6) transplanted miR-1-ES cells improve left ventricular contractility at 2 
weeks post-MI, 7) transplanted miR-1-ES cells suppress apoptosis in the chronic model 
of MI, 8) mechanism of apoptosis inhibition by miR-1-ES cells are similar in the chronic 
and acute model of MI, 9) miR-1-ES cell transplantation attenuates contractility loss at 4 
weeks following MI, 10) TIMP-1-ES cells significantly inhibit host myocardium apoptosis 
post-MI, 11) apoptosis inhibition following TIMP-1-ES cell transplantation is mediated, in 
part, through the Akt pathway, 12) transplanted TIMP-1-ES cells inhibit interstitial and 
vascular fibrosis formation as well as activation of MMP-9 post-MI, and 13) transplanted 
TIMP-1-ES cells significantly improve overall cardiac function following MI through 
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retention of functional cardiac myocytes and  maintenance of the integrity of the host 
myocardium.  Our data provided in the 3 studies underscores the potential for imploring 
genetic manipulation of ES cells to generate an ideal stem cell population for use in the 
treatment of MI.  Whether insertion of multiple microRNAs/transgenes such as miR-
1and TIMP-1 into ES cells will generate a stem cell population capable of the combined 
beneficial effects observed with miR-1-ES cells and TIMP-1-ES cells independently 
remains to be seen.  However, our research provides strong evidences of stem cell 
optimization to bring ES cell transplantation therapy from the bench to the clinic.  
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